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Perk Genetic Variation and Function in Progressive Supranuclear Palsy
Abstract
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder pathologically characterized by
intracellular tangles of hyperphosphorylated tau protein distributed throughout the neocortex, basal ganglia,
and brainstem. A genome-wide association study identified EIF2AK3 as a risk factor for PSP. EIF2AK3
encodes PERK, part of the endoplasmic reticulum’s (ER) unfolded protein response (UPR). PERK is an ER
membrane protein that senses unfolded protein accumulation within the ER lumen. Recently, several groups
noted UPR activation in Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis,
multiple system atrophy, and in the hippocampus and substantia nigra of PSP subjects. In Chapter 2, we
evaluate PERK activation in the pons, medulla, midbrain, hippocampus, frontal cortex and cerebellum in
subjects with PSP, AD, and in normal controls. We found UPR activation primarily in disease-affected brain
regions in both disorders. In PSP, the UPR was primarily activated in the pons and medulla and to a much
lesser extent in the hippocampus. In AD, the UPR was extensively activated in the hippocampus. We also
observed UPR activation in the hippocampus of some elderly normal controls, severity of which positively
correlated with both age and tau pathology but not with Aβ plaque burden. Finally, we evaluated EIF2AK3
coding variants that influence PERK activation. We show that a PERK haplotype that demonstrates increased
eIF2α kinase activity is genetically associated with increased PSP risk. The UPR is activated in disease affected
regions in PSP and the genetic and biological evidence shows that this activation increases risk for PSP and is
not a protective response.
There are two common protein coding variants of PERK, HapA and HapB, which differ by three amino acids.
Recent work indicates HapB PERK has more kinase activity in response to thapsigargin treatment than does
HapA in human β-lymphocytes. The goal of the work detailed in Chapter 3 was to: 1) replicate and expand
upon previous findings in β-lymphocytes and 2) determine which of the three amino acid coding changes is
responsible for the difference in PERK activity between HapA and HapB. This work confirms that β-
lymphocytes expressing HapB PERK show more eIF2α phosphorylation than those expressing HapA.
Paradoxically, HapB PERK cells also show less phosphorylated PERK. These findings were echoed in mouse
embryonic fibroblasts expressing PERK variant constructs. Further work exploring the functional differences
between PERK variants is warranted.
Chapter 4 discusses the implications of the work detailed in Chapters 2 and 3 and suggests future directions
for this work, including examination of post-translational modifications of PERK and exploration of how
PERK variants function in cell culture models of tauopathy.
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ABSTRACT 
PERK GENETIC VARIATION AND FUNCTION IN PROGRESSIVE SUPRANUCLEAR 
PALSY 
Lauren Denise Stutzbach 
Gerard D. Schellenberg 
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder pathologically 
characterized by intracellular tangles of hyperphosphorylated tau protein distributed 
throughout the neocortex, basal ganglia, and brainstem. A genome-wide association 
study identified EIF2AK3 as a risk factor for PSP. EIF2AK3 encodes PERK, part of the 
endoplasmic reticulum’s (ER) unfolded protein response (UPR).  PERK is an ER 
membrane protein that senses unfolded protein accumulation within the ER lumen.  
Recently, several groups noted UPR activation in Alzheimer’s disease (AD), Parkinson’s 
disease (PD), amyotrophic lateral sclerosis, multiple system atrophy, and in the 
hippocampus and substantia nigra of PSP subjects.  In Chapter 2, we evaluate PERK 
activation in the pons, medulla, midbrain, hippocampus, frontal cortex and cerebellum in 
subjects with PSP, AD, and in normal controls. We found UPR activation primarily in 
disease-affected brain regions in both disorders.  In PSP, the UPR was primarily 
activated in the pons and medulla and to a much lesser extent in the hippocampus.  In 
AD, the UPR was extensively activated in the hippocampus.  We also observed UPR 
activation in the hippocampus of some elderly normal controls, severity of which 
positively correlated with both age and tau pathology but not with Aβ plaque burden. 
vii 
 
Finally, we evaluated EIF2AK3 coding variants that influence PERK activation.  We 
show that a PERK haplotype that demonstrates increased eIF2α kinase activity is 
genetically associated with increased PSP risk.  The UPR is activated in disease 
affected regions in PSP and the genetic and biological evidence shows that this 
activation increases risk for PSP and is not a protective response. 
There are two common protein coding variants of PERK, HapA and HapB, which differ 
by three amino acids. Recent work indicates HapB PERK has more kinase activity in 
response to thapsigargin treatment than does HapA in human β-lymphocytes. The goal 
of the work detailed in Chapter 3 was to: 1) replicate and expand upon previous findings 
in β-lymphocytes and 2) determine which of the three amino acid coding changes is 
responsible for the difference in PERK activity between HapA and HapB. This work 
confirms that β-lymphocytes expressing HapB PERK show more eIF2α phosphorylation 
than those expressing HapA. Paradoxically, HapB PERK cells also show less 
phosphorylated PERK. These findings were echoed in mouse embryonic fibroblasts 
expressing PERK variant constructs. Further work exploring the functional differences 
between PERK variants is warranted. 
Chapter 4 discusses the implications of the work detailed in Chapters 2 and 3 and 
suggests future directions for this work, including examination of post-translational 
modifications of PERK and exploration of how PERK variants function in cell culture 
models of tauopathy. 
 
 
 
viii 
 
 
TABLE OF CONTENTS 
ACKNOWLEDGMENTS................................................................................................. iv 
ABSTRACT.................................................................................................................... vi 
LIST OF TABLES .......................................................................................................... ix 
LIST OF FIGURES .......................................................................................................... x 
CHAPTER 1: INTRODUCTION ...................................................................................... 1 
Progressive Supranuclear Palsy (PSP) ................................................................... 1 
Tau function and dysfunction in neurodegenerative disease ............................... 2 
Genetics of PSP ........................................................................................................ 4 
PERK and the Unfolded Protein Response (UPR) .................................................. 5 
The function and dysfunction of the UPR in disease ............................................. 7 
Novel questions addressed by this thesis .............................................................10 
Is PERK activated in disease-affected brain regions in PSP? .................................10 
Are PERK variants associated with PSP? ..............................................................10 
How do variations in the PERK protein affect activity? ............................................11 
CHAPTER 2: THE UNFOLDED PROTEIN RESPONSE IS ACTIVATED IN DISEASE-
AFFECTED BRAIN REGIONS IN PROGRESSIVE SUPRANUCLEAR PALSY AND 
ALZHEIMER’S DISEASE ..............................................................................................12 
ABSTRACT ................................................................................................................13 
INTRODUCTION .......................................................................................................14 
RESULTS ..................................................................................................................21 
DISCUSSION ............................................................................................................25 
FUNDING AND ACKNOWLEDGEMENTS .................................................................31 
CHAPTER 3: FUNCTIONAL CONSEQUENCES OF PERK GENETIC VARIATION ....49 
ABSTRACT ................................................................................................................50 
INTRODUCTION .......................................................................................................50 
MATERIALS AND METHODS ...................................................................................51 
RESULTS ..................................................................................................................55 
DISCUSSION ............................................................................................................59 
CHAPTER 4: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS .....................78 
PERK activation in neurodegenerative disease ..........................................................79 
PERK variation and its effect on PERK function .........................................................81 
REFERENCES ..............................................................................................................85 
ix 
 
 
 
LIST OF TABLES 
Table 2.1 Subject information. .......................................................................................34 
Table 2.2 Anitbodies used. ............................................................................................35 
Table 2.3  P-values for comparison of pPERK and pEIF2α immunoreactivity in PSP, AD, 
and normal controls for different brain regions. ..............................................................36 
Table 2.4 PERK haplotypes. ..........................................................................................37 
Table 2.5 SNPs in high LD with rs7571971. ..................................................................38 
Table 2.S1 Individual Case Information .........................................................................39 
Table 3.1 Primers for Site-Directed Mutagenesis ...........................................................62 
Table 3.2 PERK constructs ………………………………………………………......………62 
Table 3.3 Antibodies ......................................................................................................63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
 
 
 
LIST OF FIGURES 
Figure 2.2 peIF2α is activated in PSP, AD, and normal brain ......................................................... 42 
Figure 2.3 Frequency of pPERK staining scores in PSP, AD, and normal brain .............................. 43 
Figure 2.4 Frequency of peIF2α staining scores in PSP, AD, and normal brain. ............................ 44 
Figure 2.5 Hyperphosphorylated tau and pPERK partially co-localize in PSP pons and AD 
hippocampus .................................................................................................................................. 45 
Figure 2.6 Severity of PERK activation in normal hippocampus correlates with age and tau 
pathology ....................................................................................................................................... 46 
Figure 2.7 Comparison of PERK haplotype with GWAS risk allele ................................................. 47 
Figure 2.S1...................................................................................................................................... 48 
Figure 3.1. Thapsigargin treatment time course for peIF2α .......................................................... 65 
Figure 2.2 Relative quantification of PERK expression by qPCR .................................................... 66 
Figure 2.3 Human β-lymphocytes endogenously expressing PERK haplotype A and PERK 
haplotype B .................................................................................................................................... 68 
Figure 3.5 Quantification of PERK from Western blots ................................................................. 70 
Figure 3.6 Quantification of pPERK from Western blots ............................................................... 72 
Figure 3.7 Quantification of peIF2α from Western blots .............................................................. 74 
Figure 3.8 Quantification of ATF4 from Western blots .................................................................. 76 
Figure 9. Additional Western blot included in preceeding analysis .............................................. 77 
 
 
 
 
 
 
 
   
1 
 
CHAPTER 1: INTRODUCTION 
 
Progressive Supranuclear Palsy (PSP) 
PSP is a devastating neurodegenerative disease that presents with gaze palsy, 
gait disturbance, difficulty swallowing and speaking, and dementia (Steele, Richardson, 
& Olszewski, 1964). Patient prognosis is usually poor, and affected individuals can 
expect to survive only a few years from initial diagnosis (dell’Aquila et al., 2013). There 
are currently no drug or surgical treatments that prevent disease onset or progression, 
and symptomatic treatment for PSP has minimal, sustained clinical efficacy (Bensimon 
et al., 2009; Chang & Weirich, 2014; Cotter, Armytage, & Crimmins, 2010; Frattali, 
Sonies, Chi-Fishman, & Litvan, 1999; Golbe, 2014). Thus, it is critical to identify drug 
targets for this disease to reduce the suffering of patients and their families. 
PSP is part of a group of neurodegenerative diseases known as tauopathies, 
diseases characterized by intracellular aggregates of the protein tau in affected brain 
regions. Other diseases in this group include Alzheimer’s disease (AD), corticobasal 
degeneration (CBD), Pick’s disease, and some forms of frontotemporal dementia (FTD) 
(Kovacs, 2014). Though all of these diseases demonstrate similar tau pathology, the 
location of that pathology in the brain varies with each disorder’s symptomatic 
presentation. For example, tau aggregates are most abundant in the frontal and 
temporal cortex of patients with FTD, and these patients present with difficulty in 
executive functioning and/or language processing (behavioral-variant FTD and primary 
progressive aphasia, respectively). Tau aggregates in PSP are primarily in the 
brainstem, the location of many nuclei that control eye movement, balance, and tongue 
and throat movements, and in the basal ganglia, the brain’s general movement control 
center (Dickson, Kouri, Murray, & Josephs, 2011; Hauw et al., 1994; Irwin et al., 2014). 
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However, tauopathies present with a spectrum of pathology and clinical symptoms, and 
there is considerable overlap between them (Irwin et al., 2014; Kobylecki et al., 2015). 
This complicates diagnosis both pre- and postmortem, but also allows research into 
specific tauopathies to inform research about this class of neurodegenerative disorders 
in general. Thus, though PSP is relatively rare (Steele et al., 1964), investigation into its 
pathogenesis may be more widely applicable. 
PSP tau pathology at its least severe appears in the subthalamic nucleus, 
substantia nigra, and globus pallidus. As pathological severity increases, tau pathology 
appears progressively in the posterior frontal lobe, dentate nucleus, pons, caudate and 
anterior frontal and parietal lobes. The more brain regions tau affects the shorter the 
duration of the disease. Sub classifications of PSP, including the classical Richardson’s 
syndrome (RS), PSP-parkinsonism (PSP-P), and pure akinesia with gait freezing 
(PAGF) present with distinct pathological footprints in the brain, with the highest severity 
of tau pathology evident in RS and the lowest in PSP-P (Williams et al., 2007). The 
prognosis for RS is also significantly worse than for PSP-P (dell’Aquila et al., 2013). 
Thus, both distribution and severity of tau pathology dictate clinical presentation and 
disease duration.  
 
Tau function and dysfunction in neurodegenerative disease 
Microtubule-associated binding protein tau (MAPT) binds to tubulin and helps 
stabilize and facilitate assembly of microtubules (Hirokawa, 1994), regulate intracellular 
organelle transport and the attachment of motor proteins to tubulin (Ebneth et al., 1998; 
Sato-Harada, Okabe, Umeyama, Kanai, & Hirokawa, 1996; Trinczek, Ebneth, 
Mandelkow, & Mandelkow, 1999), and influence the structure of the neuron (reviewed in 
Shahani and Brandt 2002). Deletion of the MAPT gene produces relatively subtle 
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phenotypes in mouse models, suggesting some functional redundancy between tau and 
other MAPs (Dawson et al., 2001; Harada et al., 1994). In the brain, tau is abundantly 
expressed in axons (Binder, Frankfurter, & Rebhun, 1985), while expression in glial cells 
is more moderate (LoPresti, Szuchet, Papasozomenos, Zinkowski, & Binder, 1995). It is 
unclear whether tau’s prominence as a pathological feature of so many 
neurodegenerative diseases is a result of a loss of function, a gain of toxic function, or 
some combination of the two (Shahani & Brandt, 2002). 
Though it is a natively unfolded protein, many post-translational modifications 
(PTMs) can affect tau’s conformation and function. Many of these modifications, 
especially phosphorylation, also serve as signposts of tau pathology (Iqbal, Liu, Gong, 
Alonso, & Grundke-Iqbal, 2009; Noble, Hanger, Miller, & Lovestone, 2013). Before it 
forms tangles, tau becomes “hyperphosphorylated” (Bancher et al., 1989) and thus more 
likely to aggregate. Though mature neurofibrillary tangles (NFTs) have long been 
recognized as the pathological hallmarks of tauopathy, it may be that these aggregates 
act as therapeutic sinks for hyperphosphorylated tau (htau). In this model, it is small 
accumulations of oligomeric htau that promote neurodegeneration, not NFTs (Brunden, 
Trojanowski, & Lee, 2008; Gerson et al., 2014; Iqbal et al., 2009). 
Recent work supports the hypothesis that abnormal tau can move from one cell 
to an adjacent cell and “seed” new tau aggregation. The seeds potentially initiate 
aggregate formation by acting through a prion-like mechanism, recruiting soluble tau into 
the tangle seed (Clavaguera et al., 2009; Goedert, Clavaguera, & Tolnay, 2010; Guo & 
Lee, 2011; Sanders et al., 2014). This theory is supported by the observation that brain 
homogenates from various tauopathies can induce tangle formation when they are 
injected into mouse brain (Clavaguera et al., 2013). In AD, the cell non-autonomous 
model is consistent with the widely accepted hypothesis that tau pathology initiates in 
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the entorhinal cortex, and then spreads to the hippocampus and neocortex (Braak et al. 
2006; Braak and Braak 1991). This non-autonomous mechanism may also occur in 
PSP, in which tau pathology initiates in the brainstem. 
 
Genetics of PSP 
There is considerable phenotypic variability in the clinical presentation of PSP 
(Respondek et al., 2014), and efforts to treat it could be hindered by the difficulty of early 
diagnosis. As with many neurodegenerative diseases, the symptoms that prompt a 
patient to seek diagnosis and treatment may come too late for effective intervention, 
even once such interventions are available. Thus, it will be imperative, moving forward, 
to identify not only the earliest symptoms of disease, but also to screen people 
prospectively for risk factors. This screening could be both physiological, as in biomarker 
analysis, and genetic.  
Some mutations in the gene MAPT, which codes for tau, result in a PSP 
phenotype (Poorkaj et al., 2002; Rademakers et al., 2005; Stanford et al., 2000), further 
establishing tau’s role as a crucial player in PSP pathogenesis. A common inversion 
haplotype in MAPT also increases risk for developing PSP (Baker et al., 1999). This 
haplotype, called H1, represents an inversion of several genes in the vicinity of MAPT on 
chromosome 17, including Saitohin, NSF, IMP5, CRHR1, and LOC284058 (Pittman, 
2005; Stefansson et al., 2005). The alternative haplotype, H2, is present almost 
exclusively in Europeans and may be protective against PSP (Pau Pastor et al., 2004). 
Further work is needed to determine why H1 confers PSP risk, though the likely origin is 
MAPT itself (Pittman, 2005). 
Alternative splicing of exons 2, 3, and 10 of MAPT result in six different tau 
isoforms, each containing either one or two acidic inserts at the N-terminal end of tau 
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and three or four microtubule (MT) binding repeats near the C-terminal end of tau (3R 
tau and 4R tau; Gendron and Petrucelli 2009). The difference in number of MT binding 
repeats affects binding affinity; these tau isoforms compete for the same MT binding 
sites, and 4R tau can displace MT-bound 3R tau (M. Lu & Kosik, 2001). Pathological tau 
aggregates in PSP are composed only of 4R tau, whereas similar aggregates in Pick’s 
disease are composed of 3R tau (Buee & Delacourte, 1999). NFTs in AD are a mix of 
3R and 4R tau (Togo et al., 2004). This indicates genetic variants influencing tau 
expression and splicing may be critical in determining an individual’s risk of developing a 
particular tauopathy (Pittman, 2005). 
Schellenberg and colleagues recently completed a genome-wide association 
screen (GWAS) for additional PSP risk loci (Höglinger et al., 2011). GWASs compare 
common single nucleotide polymorphisms (SNPs) between affected and unaffected 
individuals for a particular disease or trait.  “Hit” SNPs act as signposts indicating a risk-
conferring genetic feature is nearby, and the actual risk locus is likely in strong linkage 
disequilibrium (LD) with that hit SNP. The PSP GWAS identified several genes that 
contribute to PSP risk, including STX6 (encoding syntaxin 6), MOBP (encoding myelin-
associated oligodendrocyte basic protein), and EIF2AK3 (encoding eukaryotic 
translation initiation factor 2 alpha kinase 3, also called PERK). PERK is an ER 
membrane protein that acts as a stress sensor in the ER unfolded protein response 
(UPR). 
 
PERK and the Unfolded Protein Response (UPR) 
In addition to PERK, there are two other UPR stress sensors (both of which are 
also ER membrane proteins): inositol-requiring enzyme 1α (IRE1α) and activating 
transcription factor 6 (ATF6; Ron and Walter 2007).  All arms of the UPR activate when 
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the chaperone BiP, normally bound on the luminal side of each protein, dissociates in 
order to aid in the re-folding of accumulated misfolded proteins in the ER lumen. This 
facilitates translocation and cleavage of ATF6 and exposes a phosphorylation site on 
both PERK and IRE1α (Scheper & Hoozemans, 2009).  Each of the three branches of 
the UPR initiates discrete signaling cascades in response to the accumulation of mis- or 
unfolded proteins in the ER lumen. These signaling cascades can be both protective and 
destructive to the cell. Though the protective role of the UPR is to restore homeostasis 
by attenuating translation, promoting ER-associated degradation (ERAD; Travers et al. 
2000), and upregulating chaperone production (Kozutsumi, Segal, Normington, Gething, 
& Sambrook, 1988; Matus, Glimcher, & Hetz, 2011), prolonged ER stress can trigger 
apoptosis (Rutkowski et al., 2006; Urra, Dufey, Lisbona, Rojas-Rivera, & Hetz, 2013). 
The PERK arm of the UPR acts primarily on translation. When PERK is activated 
(thus becoming phosphorylated PERK, or pPERK), a kinase domain on the cytosolic 
side of the protein phosphorylates eukaryotic translation initiation factor 2α (eIF2α). 
peIF2α then acts at the ribosome to slow down general translation initiation and promote 
translation of ATF4. ATF4 promotes the transcription of genes that enhance import of 
amino acids and protect against oxidative stress (Harding et al., 2003). However, ATF4 
also increases expression of CHOP, a transcription factor that promotes both 
dephosphorylation of eIF2α (via the phosphatase GADD34) and apoptosis (Tabas & 
Ron, 2011). 
Elements of the PERK pathway are also involved in another important cellular 
response to misfolded protein accumulation: autophagy (Rouschop et al., 2010; 
Yorimitsu, Nair, Yang, & Klionsky, 2006). UPR activation induces formation of 
autophagosome-like structures that engulf portions of the ER itself, potentially acting as 
a negative regulator of ER expansion during stress (Bernales, McDonald, & Walter, 
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2006). More specifically, PERK activation significantly upregulates transcription of 
autophagy receptor genes (Deegan et al., 2015). This upregulation of autophagy in 
response to ER stress may help restore normal cell functioning and promote cell survival 
(Ogata et al., 2006).  
Genetic variation that either alters the PERK protein or regulates the amount of 
this protein in the cell could perturb these crucial stress-response pathways and 
contribute to disease pathogenesis or progression in PSP and other neurodegenerative 
diseases. A developing body of literature supports PERK’s role as an important player in 
neurodegeneration and suggests that further study of PERK genetics and protein 
function could yield important insights into potential treatment options for these diseases 
(Hetz & Mollereau, 2014). 
 
The function and dysfunction of the UPR in disease 
Previous work showed that the UPR is activated in post-mortem brains from AD 
(Jeroen J M Hoozemans et al., 2009), Parkinson’s disease (J J M Hoozemans et al., 
2007), amyotrophic lateral sclerosis (Atkin et al., 2008; Wang, Popko, & Roos, 2010), 
frontotemporal dementia (D. A. T. Nijholt, van Haastert, Rozemuller, Scheper, & 
Hoozemans, 2012) and multiple system atrophy (Makioka et al., 2010) patients. The 
UPR is also activated in PSP (Stutzbach et al., 2013, see Chapter 2) All of these 
disorders, PSP included, are characterized by pathological aggregates of misfolded 
proteins in the brain. The UPR tends to be activated in cells with early-stage staining for 
neuropathological proteins (usually a diffuse staining pattern) rather than full-blown 
tangles or inclusions, suggesting that activation of the UPR is an early event in disease 
(Jeroen J M Hoozemans et al., 2009; Makioka et al., 2010; D. A. T. Nijholt et al., 2012). 
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Activation of the UPR generally and PERK specifically could influence 
neurodegeneration in several ways. First, it is important to note that tau aggregates are 
primarily cytoplasmic and do not generally traffic through the ER (Congdon & Duff, 
2008). This means that misfolded tau is not directly triggering the UPR via accumulation 
in the ER lumen. However, large protein aggregates or small, toxic accumulations of 
htau oligomers could interfere with cytoplasmic components of the UPR signaling 
machinery, particularly endoplasmic reticulum-associated degradation (ERAD) and 
autophagy. A “backlog” of cytoplasmic proteins targeted for degradation could interfere 
with the normal degradation of misfolded proteins exported from the ER and could 
impede upregulation of protein degradation (Abisambra et al., 2013). This downstream 
roadblock could initiate prolonged ER stress and bias the cell toward apoptosis (Urra et 
al., 2013). 
Another way PERK activity may influence neurodegeneration is via translational 
inhibition. Though this global decrease in protein translation may be helpful in the short 
term, prolonged lack of protein synthesis is ultimately detrimental. Work from Moreno et 
al. (2012) showed that prion infected mice demonstrated prolonged phosphorylation of 
eIF2α along with synaptic deficits and neurodegeneration. However, overexpression of 
GADD34, an eIF2α phosphatase (Ron & Walter, 2007), restored translation and rescued 
several prion disease phenotypes, increasing survival. Conversely, treatment with 
salubrinal, an inhibitor of eIF2α phosphatases (Boyce et al., 2005), exacerbated neuron 
loss and decreased survival. This could indicate that translational repression mediated 
by sustained eIF2α phosphorylation interferes with normal neuronal function and may 
bias the cell toward degeneration. 
Though moderate PERK depletion might prove beneficial in the case of 
neurodegeneration, complete loss of PERK could be detrimental. The developmental 
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disorder Wolcott-Rallison syndrome results from PERK insufficiency (Delépine et al., 
2000). Wolcott-Rollin presents with skeletal dysplasia, growth retardation, and diabetes 
mellitus (Stöss, Pesch, Pontz, Otten, & Spranger, 1982). PERK knockout in a mouse 
model results in a similar phenotype (Peichuan Zhang et al., 2002). Thus, any treatment 
targeting PERK would need to modulate rather than eliminate its activity. Indeed, a 
follow-up study from  Moreno et al.(2013) showed that though treatment with a selective 
PERK inhibitor rescued several disease phenotypes in prion-infected mice, it also 
increased glucose levels and resulted in a 20% decrease in body weight.  
Phosphorylation of eIF2α also plays a role in synaptic plasticity and memory 
(Hetz & Mollereau, 2014). Conditional PERK knockout in an APP-PS1 mouse line 
rescues Aβ-related defects in spatial memory and long-term potentiation (LTP; Ma et al. 
2013). The effect is similar for knockout of GCN2, another eIF2α kinase. Without the de 
novo protein synthesis that is largely blocked by prolonged eIF2α phosphorylation, 
memory formation and consolidation are severely impaired. Thus, stress conditions in 
the cell that continuously trigger eIF2α kinases like PERK and GCN2 may be partially 
responsible for memory-related symptoms of neurodegeneration. Likewise, any 
alterations to PERK that increase its eIF2α kinase activity could directly contribute to 
neurodegenerative disease pathogenesis or progression. 
Recent work from Liu et al. (2012) demonstrated that there are two common 
PERK coding haplotypes, designated Haplotype A (HapA; more common) and 
Haplotype B (HapB; less common). In human β-lymphocytes, cells homozygously 
expressing HapB demonstrated significantly more eIF2α phosphorylation in response to 
treatment with the ER stress-inducing drug thapsigargin (Rogers, Inesi, Wade, & 
Lederer, 1995) than did cells expressing HapA. Interestingly, the three SNPs that confer 
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the coding differences between HapA and HapB are in strong LD with the PSP GWAS 
SNP giving the strongest signal in the PERK gene (Höglinger et al., 2011; Stutzbach et 
al., 2013). This presents a potential pathogenic mechanism for PERK’s involvement in 
PSP and is the focus of this thesis. 
 
Novel questions addressed by this thesis 
 
 Is PERK activated in disease-affected brain regions in PSP? 
There is evidence of UPR activation in Alzheimer’s disease (AD), Parkinson’s 
disease (PD), amyotrophic lateral sclerosis, multiple system atrophy, and in the 
hippocampus and substantia nigra of PSP subjects (Atkin et al., 2008; J J M Hoozemans 
et al., 2007; Jeroen J M Hoozemans et al., 2009; Makioka et al., 2010; D. A. T. Nijholt et 
al., 2012; Wang et al., 2010).  In Chapter 2 of this thesis, I evaluate PERK activation in 
the pons, medulla, midbrain, hippocampus, frontal cortex and cerebellum in subjects 
with PSP, AD, and in normal controls. UPR activation may be an early event in 
neurodegenerative pathogenesis (Jeroen J M Hoozemans et al., 2009). Therefore, I also 
determine whether this activation co-localizes with pre-tangle tau pathology, both in 
disease and normal controls. 
 
 Are PERK variants associated with PSP? 
 Schellenberg and colleagues recently completed a genome-wide association 
screen (GWAS) for PSP risk loci (Höglinger et al., 2011).  One of the genes identified 
was eukaryotic translation initiation factor 2 alpha kinase 3 (EIF2AK3 or PERK). The 
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SNP identified in the PSP GWAS is in strong LD with two common PERK haplotypes 
that differ at three amino acids: S136-R166-A704 (low risk allele, called HapA) or C136-
Q166-S704 (higher risk allele, called HapB). In the second part of Chapter 2, I examine 
whether these PERK coding haplotypes are associated with PSP risk. 
 
 How do variations in the PERK protein affect activity? 
These coding changes are potentially functional variants of PERK and may affect 
its role in the UPR. Work from Liu et al. (2012) showed that HapB PERK has a stronger 
response to drug-induced ER stress than HapA PERK. Also, at least one of the three 
coding changes, S136C (rs867529), is predicted by several methods to be a deleterious 
substitution for PERK (Burke et al., 2007).  Thus, the goal of the second part of my 
thesis is to replicate the findings of Liu et al. (2012) and to determine which of the three 
amino acid variations that comprise the PERK haplotypes are responsible for this 
functional difference. To do this, I first examine phosphorylation of PERK and eIF2α in 
human β-lymphocytes. I then express artificial PERK variant constructs with single 
amino acid alterations in mouse embryonic fibroblasts (MEFs) derived from PERK null 
mice and assess phosphorylation of PERK and eIF2α as well as ATF4. 
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ABSTRACT 
Background: Progressive supranuclear palsy (PSP) is a neurodegenerative disorder 
pathologically characterized by intracellular tangles of hyperphosphorylated tau protein 
distributed throughout the neocortex, basal ganglia, and brainstem. A genome-wide 
association study identified EIF2AK3 as a risk factor for PSP. EIF2AK3 encodes PERK, 
part of the endoplasmic reticulum’s (ER) unfolded protein response (UPR).  PERK is an 
ER membrane protein that senses unfolded protein accumulation within the ER lumen.  
Recently, several groups noted UPR activation in Alzheimer’s disease (AD), Parkinson’s 
disease (PD), amyotrophic lateral sclerosis, multiple system atrophy, and in the 
hippocampus and substantia nigra of PSP subjects.  Here, we evaluate UPR PERK 
activation in the pons, medulla, midbrain, hippocampus, frontal cortex and cerebellum in 
subjects with PSP, AD, and in normal controls.  Results: We found UPR activation 
primarily in disease-affected brain regions in both disorders.  In PSP, the UPR was 
primarily activated in the pons and medulla and to a much lesser extent in the 
hippocampus.  In AD, the UPR was extensively activated in the hippocampus.  We also 
observed UPR activation in the hippocampus of some elderly normal controls, severity of 
which positively correlated with both age and tau pathology but not with Aβ plaque 
burden. Finally, we evaluated EIF2AK3 coding variants that influence PERK activation.  
We show that a haplotype associated with increased PERK activation is genetically 
associated with increased PSP risk.  Conclusions: The UPR is activated in disease 
affected regions in PSP and the genetic evidence shows that this activation increases 
risk for PSP and is not a protective response. 
Keywords:  Progressive supranuclear palsy; PERK; Unfolded protein response; 
EIF2AK3; Alzheimer’s disease 
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INTRODUCTION 
Progressive supranuclear palsy (PSP) is a late-onset neurodegenerative movement 
disorder clinically characterized by vertical gaze palsy, poor balance and frequent falls, 
as well as cognitive impairment and dementia (Litvan, 1998; Steele et al., 1964).  The 
primary symptoms of PSP are consistent with the observed neuropathology, mainly 
neuronal degeneration in the brainstem, particularly the pons and medulla (Dickson, 
Rademakers, & Hutton, 2007).  Postmortem pathological analysis of these brain regions 
in PSP patients reveals numerous intracellular neurofibrillary and glial tangles comprised 
of hyperphosphorylated protein tau (htau).  Thus PSP, along with Alzheimer’s disease 
(AD), belongs to a group of disorders collectively known as tauopathies, as all these 
disorders show abundant tau aggregates or inclusions as prominent neuropathologic 
features. Other tauopathies include frontotemporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17), corticobasal degeneration (CBD), and Pick’s disease 
(Ballatore, Lee, & Trojanowski, 2007). Some mutations in the gene MAPT, which 
encodes tau, can result in a PSP phenotype (P Pastor et al., 2001; Poorkaj et al., 2002; 
Ros et al., 2005; Rossi et al., 2004; Stanford et al., 2000), while common variants in the 
MAPT region are associated with PSP susceptibility (Baker et al., 1999; Conrad et al., 
1997; Cruchaga et al., 2009; Höglinger et al., 2011). Thus, genetic studies as well as our 
data here indicate that tau is clearly linked to PSP pathogenesis. 
Schellenberg and colleagues recently completed a genome-wide association study 
(GWAS) for PSP risk loci (Höglinger et al., 2011).  One of the genes identified was 
eukaryotic translation initiation factor 2 alpha kinase 3 (EIF2AK3), which encodes the 
protein pancreatic endoplasmic reticulum kinase (PERK).  PERK is an endoplasmic 
reticulum (ER) membrane protein that acts as a stress sensor in the ER unfolded protein 
response (UPR).  In addition to PERK, there are two other stress sensors (both of which 
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are also ER membrane proteins): inositol-requiring enzyme 1α (IRE1α) and activating 
transcription factor 6 (ATF6; Ron & Walter, 2007).   
All three arms of the UPR activate when the chaperone immunoglobulin binding 
protein (BiP), normally bound on the luminal side of each protein, dissociates in order to 
aid in the folding of accumulated unfolded proteins in the ER lumen. Dissociation of BiP 
from PERK and IRE1α facilitates their activation by promoting homodimerization and 
trans-autophosphorylation (Walter & Ron, 2011).  ATF6 is then activated via a cleavage 
event and subsequently translocated from the ER to the  nucleus (Scheper & 
Hoozemans, 2009).  Each of the three branches of the UPR initiates discrete signaling 
cascades in response to the accumulation of unfolded proteins in the ER lumen. The 
role of the UPR is to restore protein homeostasis by upregulating chaperone production 
(Kozutsumi et al., 1988; Matus et al., 2011), attenuating translation, promoting 
degradation of misfolded proteins via ER-associated degradation (ERAD; Travers et al., 
2000), and promoting autophagy (D. a T. Nijholt et al., 2011). Prolonged ER stress can 
trigger apoptosis (Ron & Walter, 2007; Rutkowski et al., 2006).  
The PERK arm of the UPR acts primarily on translation.  When PERK is activated 
(thus becoming phosphorylated PERK, or pPERK), a kinase domain on the cytosolic 
side of the protein phosphorylates eukaryotic translation initiation factor 2α (eIF2α or 
peIF2α when phosphorylated).  peIF2α is a less active form of the protein, and its 
decreased efficiency slows general translation initiation and promotes translation of 
activating transcription factor 4 (ATF4).  ATF4 promotes transcription of genes that 
enhance amino acid uptake and protect against oxidative stress (Harding et al., 2003). 
Elements of the PERK pathway are also involved in regulating autophagy, a process that 
degrades misfolded proteins (Bernales et al., 2006; Rouschop et al., 2010).  Thus, 
genetic variation that results either in alteration of PERK protein function or significant 
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changes in the amount of PERK would perturb several crucial stress-response 
pathways. 
Several neurodegenerative disorders, including PSP, are characterized by 
pathological aggregates of misfolded proteins in the brain. Previous work showed that 
the UPR is activated in post-mortem AD brains (Jeroen J M Hoozemans et al., 2009), as 
well as in the brains of patients with frontotemporal lobar degeneration with tau 
inclusions (FTLD-tau) (D. A. T. Nijholt et al., 2012), PD (J J M Hoozemans et al., 2007), 
amyotrophic lateral sclerosis (ALS; Atkin et al., 2008; Wang et al., 2010), and multiple 
system atrophy (MSA; Makioka et al., 2010). Nijholt et al. (2011) reported evidence of 
UPR activation in the hippocampus and, to a lesser extent, the locus ceruleus and 
putamen of PSP patients.  
We investigated activation of PERK and eIF2α in postmortem brains from subjects 
with PSP and AD, as well as from normal elderly subjects.  We used antibodies that 
recognize the phosphorylated species of PERK and eIF2α, i.e. the activated forms of 
these 2 proteins (pPERK and peIF2α, respectively).  Our primary goal was to investigate 
the brain regions most affected by tau pathology in PSP. We searched for evidence of 
PERK and eIF2α activation in the pons, medulla and midbrain, regions affected in PSP, 
in the hippocampus and frontal cortex, which are regions affected in AD, and in the 
cerebellum, a brain region which is relatively spared in both diseases, although the deep 
cerebellar nuclei and cerebellar cortex may harbor modest amounts of tangles and 
plaques, in PSP and AD, respectively.  We also looked at PERK and eIF2α activation in 
young controls to determine if ER stress is activated in normal aging.   Our results 
indicated that PERK and eIF2α activation parallels the pattern of neuropathology in PSP 
and AD.  In normal hippocampus, activation increases with age and correlates with tau 
but not Aβ amyloid pathology.  We also examined coding haplotypes that were 
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previously shown to affect PERK activation (Liu et al., 2012).  We found that the 
haplotype that corresponds to the highest PERK activation is in linkage disequilibrium 
(LD) with the high risk allele of the top PSP GWAS marker, indicating that UPR 
activation increases PSP risk and is not a protective response in PSP. 
MATERIALS AND METHODS 
Human Tissue 
We obtained postmortem human pons, medulla, midbrain, frontal cortex, hippocampus, 
and cerebellum samples from the Center for Neurodegenerative Disease Research 
(CNDR; University of Pennsylvania School of Medicine, Philadelphia, PA) using the 
CNDR Integrated Neurodegenerative Disease Database (Xie et al., 2011) and from the 
Michigan Alzheimer's Disease Research Center Brain Bank (MADRC; University of 
Michigan, Ann Arbor, MI).  We chose PSP and AD cases for lack of co-morbid 
diagnoses and availability of fixed tissue-- PSP and AD cases with a secondary 
neuropathological diagnosis (NPDx; for instance, PD) were excluded from the present 
study.  All PSP and AD cases were evaluated by a neurologist pre-mortem and referred 
to the CNDR or MADRC brain donation programs, where a neuropathologist made a 
NPDx according to established criteria (Hyman & Trojanowski, 1997; Litvan et al., 1996). 
Controls had no clinical history or postmortem diagnosis of a neurodegenerative 
disease. One control displayed a moderate amount of Lewy body pathology in the 
medulla and another displayed a mild amount of tau deposition in the midbrain (though 
not in the substantia nigra). All control cases were free of Lewy bodies in the 
hippocampus. We age-matched all cases and controls (See Table 2.1 and Table 2.S1 
for demographic information). Tissue used for immunohistochemical and 
immunofluorescence studies was fixed in either ethanol (70%) or 10% neutral buffered 
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formalin overnight and then processed for paraffin embedding and 6µm thick sections 
were generated as described (Heiko Braak et al., 2006) using a Leitz 1512 microtome. 
The average age of PSP, AD, and normal controls was approximately 75 years. Average 
disease duration for PSP patients was 6.7 years, while the average duration for AD 
patients was 10.8 years. The average post-mortem interval (PMI) for all cases was 10.2 
hours (Table 2.1, Table 2.S1). Pontine sections included the locus coeruleus and 
surrounding tegmentum, midbrain sections included the substantia nigra, medulla 
sections included the olivary nucleus, hippocampal sections included the CA and 
dentate regions, frontal cortex sections included both white and gray matter, and 
cerebellar sections included the folia. 
Immunohistochemistry  
Immunohistochemistry was performed as previously described (Arnold et al., 2010; 
Lippa et al., 2009). We deparaffinized brain sections on slides using xylene (Mallinckrodt 
Baker Inc., Phillipsburg, NJ), and then hydrated  them through a series of ethanol 
washes, and quenched endogenous peroxidases by immersing sections in a mixture of 
hydrogen peroxide and methanol.  Following a wash in running water, we performed 
antigen retrieval by microwaving sections immersed in citrate buffer (Thermo Shandon 
Limited, Astmoor, WA).  We then washed sections in 0.1M Tris (pH 7.6; Fisher 
Scientific), blocked in 0.1M Tris (pH 7.6)/2% fetal bovine serum (FBS), and applied 
primary antibody (incubated overnight at 4o).  This wash/block procedure was identical 
for secondary antibody application, with an incubation time of one hr.  Following another 
wash, we applied avidin/biotin complex (Vector Labs) to each section and incubated the 
sections for one hr.  Finally, we developed sections with DAB chromagen (Biogenex), 
counterstained with hematoxylin, dehydrated through a series of ethanol and xylene 
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washes.  Cover slips were sealed with Cytoseal (Richard Allen Scientific, Kalamazoo, 
MI).  Antibodies used are listed in Table 2.2. 
Immunofluorescence (IF) 
We deparaffinized, hydrated, quenched, and performed antigen retrieval on slide-
mounted sections as described above.  We then blocked sections in 0.1M Tris/2% FBS, 
and applied mouse and rabbit primary antibodies (diluted in 0.1M Tris/2% FBS).  Primary 
antibody incubation time was 2 hr at room temperature.  Following a wash in 0.1M Tris 
and transfer to a “dark” chamber, we applied secondary antibodies (goat-anti-mouse and 
goat-anti-rabbit; Vector Labs) and let sections incubate for another two hours at room 
temperature.  We then washed the sections again and applied 0.3% Sudan Black in 70% 
ethanol (Romijn et al., 1999) for five min to quench endogenous lipofuscin related 
flourophores.  After another wash, the sections were coverslipped using Vectashield 
(with DAPI; Vector Labs; Uryu et al., 2003). 
Slide Scoring and Analysis 
pPERK and peIF2 antibodies both stained cells in a characteristic punctate pattern (Fig. 
2.1a and 2.2a; (J J M Hoozemans et al., 2007; Jeroen J M Hoozemans et al., 2009). We 
scored each tissue section for pPERK or peIF2α IHC staining according to the following 
scale: negative (-): no cells stained, rare (R): 1-3 cells stained, +: 4-20 cells stained, ++: 
20+ cells stained, could have diffuse distribution of stained cells, may have high density 
of stained cells in some fields of the section, +++: high density of stained cells in almost 
every field of the section. A second rater confirmed scores in 20% of randomly selected 
slides (see Fig. 2.S1). For double IF of hyperphosphorylated tau (htau) and pPERK, we 
visualized and photographed 10 fields per section and manually counted the number of 
htau positive cells, the number of pPERK positive cells, and the number of cells positive 
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for both pPERK and htau.  We scored all sections blind to disease group on an Olympus 
CHBS microscope (IHC) or an Olympus BX60 Transmitted-Reflected Light Microscope 
with BF/DF/DIC/Polarized Light and a SPOT RT Color digital microscope camera (IF).  
Statistical analysis 
We used Spearman correlations to examine correlations between level of tau pathology 
vs. pPERK staining and age vs. pPERK staining, Fisher’s exact test to examine 
association between disease condition and pPERK/peIF2α staining, Chi Square to 
examine sex distribution among disease/normal groups, ANOVA to examine the mean 
difference among disease/normal groups for average age at death and post-mortem 
interval, and a Student’s t-test to examine the mean difference between disease groups 
for average age of onset. All statistical analyses were two-sided. Statistical significance 
was set at the 0.05 level unless otherwise indicated.  
Analysis of linkage disequilibrium around rs7571971.  
In a recent GWAS for PSP risk loci (Höglinger et al., 2011), a significant association was 
established between PSP risk and rs7571971. This SNP falls in an intron of EIF2AK3, 
the gene encoding PERK. While it is reasonable to assume the SNP somehow affects 
risk for PSP by affecting expression of EIF2AK3, it remains to be proven. To garner 
genetic evidence for this hypothesis, we first evaluated the pattern LD in sequence data 
from the 1000 Genomes project (Abecasis et al., 2012) and pairwise LD evaluated using 
SNAP (Suite of Nucleotide Analysis Programs, Johnson et al., 2008). Based on these 
results, we genotyped 1043 PSP patients using TaqMan SNP Genotyping Assays 
(Applied Biosystems, Foster City, CA) for the following four SNPs: rs7571971, rs867529 
(S136C), rs1805165 (S704A), and rs13045 (R166Q; Table 2.3).  All cases were 
autopsied and had a neuropathologic diagnosis of PSP (Hauw et al., 1994).  Genotyping 
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was done according to manufacturer’s protocol. PCR conditions were as follows: 95°C 
for 10 minutes, then 50 cycles of 92°C for 15 seconds, 60°C for 1 minute, 4°C for 2 
minutes. Genotypes were visualized and called using a 7900HT Fast Real Time PCR 
System and the allelic discrimination function of Sequence Detection System V.2.4 
(Applied Biosystems, Foster City, CA). Finally, we phased the resulting four-SNP 
genotypes using eHap software (Seltman, Roeder, & Devlin, 2003), which provides 
maximum likelihood estimates of haplotype frequencies. 
RESULTS 
The PERK arm of the UPR is activated in PSP 
To determine whether the UPR is activated in PSP, we stained post-mortem human 
brain tissue from PSP and AD patients as well as normal elderly controls using 
antibodies against pPERK and peIF2α, the activated forms of these proteins.  We chose 
six brain areas to stain for PERK and eIF2α activation: the pons, medulla, and midbrain 
(affected in PSP), the hippocampus and frontal cortex (affected in AD), and the 
cerebellum, which is relatively spared in both diseases. 
In PSP cases, of the regions tested, the pons, medulla, and midbrain 
demonstrated the highest degree of pPERK and peIF2α staining (Fig. 2.1b, Fig. 2.2b, 
Fig. 2.3a-c, and Fig. 2.4a-c) as measured by number of cells showing staining per field 
(Fig. 2.S1). These are the brain areas most affected by tau pathology in PSP.  pPERK 
and peIF2α staining was punctate and cytoplasmic with some non-specific nuclear 
staining (Fig. 2.1a and Fig. 2.2a), a pattern observed by others in AD and PD (J J M 
Hoozemans et al., 2007; Jeroen J M Hoozemans et al., 2009). In the pons, all PSP 
cases showed some cells positive for both pPERK and peIF2α.  pPERK was observed in 
the medulla and midbrain in all but one case for each region.  For peIF2α, all cases 
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showed positive cells in the medulla and all but one case showed positive cells in the 
midbrain.  
PSP cases as a group showed significantly more pPERK and peIF2α staining in 
the pons, medulla, and midbrain compared to elderly controls.  For pPERK, only one 
control subject (age 63) showed “rare” positive cells in the pons and medulla. This is not 
the same control subject that displayed Lewy body pathology in the medulla. In the 
midbrain, very few controls were positive for pPERK.  For peIF2α, most controls were 
negative in these brain areas except for a single subject with rare positive cells in the 
medulla.  For AD, there were more positive cases with a higher density of positive cells 
compared to controls but less than found in PSP (Fig. 2.3 and 2.4, a-c, Table 2.3).   
In the hippocampus and frontal cortex, AD cases as a group scored significantly 
higher than PSP or normal elderly controls for both pPERK and peIF2α staining (Table 
2.3).  pPERK and peIF2α staining was especially strong in the AD hippocampus, with 
nearly all cases demonstrating high levels of positive cells. All PSP cases had mild to 
moderate pPERK staining in the hippocampus, though not all cases demonstrated 
peIF2α staining.  Surprisingly, many normal elderly controls demonstrated at least a mild 
level of pPERK and peIF2α positive cells in the hippocampus (Fig. 2.1c, Fig.2.2c, Fig. 
2.3d, and Fig. 2.4d). Staining was generally milder in the frontal cortex than in the 
hippocampus, although AD cases still scored significantly higher than PSP cases or 
normal controls (Fig. 2.3e and Fig. 2.4e).  PSP cases scored significantly higher than 
normal controls for pPERK staining but not for peIF2α staining (Table 2.3).  Notably,  the 
pons, medulla, and midbrain are severely affected in PSP [2] but only moderately or 
mildly affected in AD (Serrano-Pozo, Frosch, Masliah, & Hyman, 2011). Conversely, the 
hippocampus and frontal cortex are strongly affected in AD (Serrano-Pozo et al., 2011), 
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but only mildly affected or unaffected in PSP. Thus, PERK activation is strongest in 
areas of the brain highly affected by pathology in PSP and AD. Nearly all cases were 
negative for pPERK and peIF2α in the folia of the cerebellum (Fig. 2.1d, Fig. 2.2d, Fig. 
2.3f, and Fig. 2.4f), although one AD case showed rare staining in this area. Regardless, 
there is generally little to no pathology in this area in PSP or AD, and thus our findings 
are consistent with the inference that pathology and PERK activation occur in the same 
disease-affected brain areas. 
Activation of pPERK in hTau Positive Cells  
We were interested in whether the UPR is activated in cells affected by tau pathology.  
We performed double immunofluorescence staining for pPERK and htau on sections of 
pons and hippocampus in PSP, AD, and normal controls (Fig. 2.5a).  In PSP pons, an 
average of 72% of pPERK positive cells were also positive for htau.  However, only 43% 
of htau positive cells were also positive for pPERK (Fig. 2.3c). This substantial overlap is 
in contrast to AD hippocampus, in which only 20% of pPERK positive cells also stained 
for htau and only 12% of htau positive cells stained for pPERK (Fig. 2.3d). Overlap 
between htau and pPERK staining was also low in PSP and normal hippocampus (data 
not shown).  In the pons, overlap between pPERK puncta and htau occurred mostly in 
cells with diffuse, cytoplasmic htau staining rather than dense, fibrillar staining (Fig. 
2.3b). This suggests that PERK is activated in pre-tangle neurons. Hoozemans et al. 
(2009) described similar distribution of htau/pPERK staining in AD hippocampus.  
PERK is activated in normal hippocampus 
Unexpectedly, we found pPERK and peIF2α staining in the hippocampus of age-
matched elderly normal controls as described above. To follow up on this finding, we 
expanded our initial control hippocampus sample to include cases with a wide range of 
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ages (range: 16-92, mean: 52.4; see Table 2.S1). We found that age significantly 
correlated with the pPERK staining score (Fig. 2.6a). The older the subject, the more 
likely they were to have high levels of PERK activation in the hippocampus. However, 
not all aged normal controls demonstrated hippocampal pPERK activation although 
some subjects at all ages examined here were negative for pPERK staining. 
We also found that the level of tau pathology correlated with pPERK staining. 
The more tau pathology (as measured by PHF-1 staining) in a normal hippocampus, the 
more likely that the hippocampus was also positive for activated PERK (Fig. 2.6b). All 
controls negative for pPERK staining were also negative for htau staining; cases with 
severe pPERK staining scores also scored high for htau. This correlation was significant 
(Spearman R: 0.7523, p = .0002). There was no correlation between pPERK staining in 
the hippocampus and Aβ amyloid plaque pathology (as measured by Thioflavin S 
staining to detect senile plaques); all normals with high pPERK scores and relatively 
high tau scores in the hippocampus were negative for Aβ amyloid plaques and Lewy 
bodies (data not shown).  
PERK protein coding variants are associated with PSP risk 
Alleles at rs7571971 are significantly associated with PSP risk [10].  To identify other 
SNPs in high linkage disequilibrium with rs7571971, we evaluated 1000 Genomes data 
for subjects of European ancestry. As assessed by LD measure r2 (Devlin & Risch, 
1995), 14 SNPs were in high LD with rs7571971 (r2 > 0.8), including the 3 non-
synonymous coding variants. Of these 14, none fell in the coding region of any gene 
besides EIF2AK3 and all but 5 fell within EIF2AK3 (Table 2.5). 
The 3 non-synonymous coding variants in EIF2AK3 were Ser136Cys, 
Arg166Gln, and Ser704Ala.  When haplotypes were constructed from 1000 Genome 
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data, there were two common haplotypes Ser-Arg-Ser (haplotype A) and Cys-Gln-Ala 
(haplotype B) with predicted  frequencies of 0.64 and 0.29, respectively; one uncommon 
haplotype, Ser-Gln-Ser (haplotype D), with a frequency of 0.06; and 4 rare haplotypes of 
frequency close to 1/1000 . The top PSP GWAS SNP for this gene is rs7571971, a 2-
allele polymorphism in EIF2AK3 intron 2 with a minor allele frequency of 0.25-0.28 
(Höglinger et al., 2011).  From the 1000 genome analysis, the minor allele for rs7571971 
is almost perfectly correlated with haplotype B and the major allele with haplotypes A 
and D.   
To confirm the relationship of LD amongst SNP alleles in PSP subjects, we 
genotyped 1,043 PSP cases for rs7571971, and the 3 coding variant SNPs.  The 
genotypes for these four SNPs were then phased using maximum likelihood. We 
observed that, in PSP cases, haplotype frequencies were almost identical to those from 
1000 Genomes data: for A, 0.645 versus 0.642; for B, 0.288 versus 0.301; and for D, 
0.061 versus 0.053. Again haplotypes A and D are completely correlated with rs7571971 
allele C (Fig. 2.7), the protective PSP allele. Haplotype B is completely correlated with 
allele T, the high risk PSP allele. Recently Liu et al (2012) showed that when 
lymphoblastoid cell lines are treated with thapsigarin to induce ER stress, cells 
homozygous for the B haplotype showed stronger activation than cells homozygous for 
the A haplotype.  Thus B is the high-risk haplotype for PSP suggesting that activation is 
not a protective response, but rather increases risk for PSP.  
DISCUSSION 
We found that PERK is activated in disease-affected brain regions in PSP, 
including the pons, medulla, and midbrain. We also found that PERK’s downstream 
effector, eIF2α, is activated similarly in PSP brainstem areas. In contrast, PERK and 
eIF2 are not activated or only weakly activated in normal and AD brainstem, 
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respectively. We confirmed that AD cases have strong immunoreactivity for pPERK and 
peIF2α in the pyramidal cells of the hippocampus (Jeroen J M Hoozemans et al., 2009) 
and in the frontal cortex.   In contrast, PSP cases show mild to moderate pPERK 
staining in these regions (D. A. T. Nijholt et al., 2012).  PERK and eIF2α were not 
activated in the cerebellum in either disease.  In AD and PSP, the pattern of UPR 
activation parallels the regional distribution of pathology in these two disorders. 
We explored the relationship between abnormal tau deposits and UPR activation 
in the PSP brainstem. Although there is some overlap between cells with activated 
PERK and cells with htau, at least half of htau-positive cells do not have concurrent 
PERK activation. A greater proportion of pPERK positive cells were also positive for tau, 
but 25% stained for pPERK alone. Thus, although PERK is activated in brain regions 
highly affected by tau pathology, htau and pPERK do not necessarily overlap at the 
single cell level.  One potential explanation for lack of complete overlap may be that 
PERK activation precedes tangle formation, and is no longer activated in cells with 
mature tangles. We found that overlap between pPERK and htau mostly occurred in 
cells with diffuse htau staining rather than dense tau staining, supporting this hypothesis. 
Similarly, Hoozemans et al. (2009) found that cells in the AD hippocampus that were 
positive for pPERK also stained for markers of early tau aggregation (Jeroen J M 
Hoozemans et al., 2009). This evidence suggests that PERK activation may temporally 
precede overt tau aggregation, and could be triggered by immunohistochemically 
undetectable levels of abnormal tau.  The genetic data implicating both PERK and tau in 
PSP supports a plausible temporal relationship between PERK activation and tau 
aggregation.   
Genetic findings (Höglinger et al., 2011) and the data presented here implicate 
PERK as well as the UPR in the pathogenesis of PSP.    Genetic findings also associate 
MAPT with PSP (Höglinger et al., 2011; Poorkaj et al., 2002; Rademakers et al., 2005; 
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Tsuboi, Josephs, Cookson, & Dickson, 2003), and along with the presence of 
aggregated tau as the key neuropathologic feature of PSP, these data clearly establish 
that tau is intimately linked to PSP pathogenesis.   While the UPR is activated by 
misfolded proteins within the ER, and aggregated misfolded tau occurs in PSP, AD, and 
other tauopathies, tau is a cytosolic protein and does not appear to traffic through the ER 
as part of a secretory pathway.  In normal neurons, most tau protein is intracellular and 
attached to microtubules. In tauopathies, tau aggregates in the cytoplasm of cells, in 
cellular processes, and at nerve terminals, but there is no evidence that tau aggregates 
in the ER.  Recent work in mouse models of α-synucleinopathies and studies on PD 
autopsy material (E. Colla et al., 2012; Emanuela Colla et al., 2012)  suggest that small 
amounts of α-synuclein can be found in ER, and that in the disease state, these levels 
are elevated, thereby activating the ER stress response. Still, since there is no direct 
evidence that tau traffics through the ER, or evidence of tau aggregates in the ER, it is 
unlikely that misfolded tau directly activates the canonical UPR.  This view is supported 
by the fact that in PSP, pPERK and pEIF2α are activated in cells with no observable tau 
pathology, but we cannot exclude the possibility that very low or undetectable levels of 
aggregated tau are present.  Rather, a more likely explanation is that tau-induced 
cytoplasmic events act to trigger the UPR by an unknown mechanism, which in turn 
influences the degradation of tau. A possible mechanism is that cytoplasmic aggregated 
tau may inhibit processes such as the ERAD-proteosome pathway used by cells to 
degrade misfolded ER proteins, and thus preventing the normal degradation of these 
proteins, stimulating ER stress (Abisambra et al., 2013).   
PERK and eIF2α are also activated in pathology-associated regions of a number of 
other neurodegenerative diseases, including another tauopathy, AD (Jeroen J M 
Hoozemans et al., 2009). The UPR is also activated in non-tau diseases that include 
ALS where UPR activation is observed in the spinal cord in sporadic cases (Atkin et al., 
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2008), and in PD where UPR activation occurs in the substantia nigra (J J M 
Hoozemans et al., 2007). Expanded-repeat huntingtin, the pathological protein in 
Huntington’s disease, induces ER stress in culture (Lajoie & Snapp, 2011). Notably, 
these diseases share a common pathology, i.e. the accumulation of abnormal 
aggregated proteins in the CNS.  Thus, there may be a common mechanism by which 
aggregated cytoplasmic proteins activate the UPR.  The genetic association between 
PERK and PSP suggests that this UPR activation can influence the disease process, at 
least in the case of PSP. 
  Surprisingly, we found that 10/14 normal controls over 50 years of age had at 
least minimal activation of pPERK in the hippocampus. This is in contrast to previous 
studies that report no pPERK staining in this region in normal controls (D. A. T. Nijholt et 
al., 2012). In these subjects, the degree of pPERK immunoreactivity correlated positively 
with both the degree of htau immunoreactivity and age, but did not correlate with amyloid 
pathology.  The presence of at least some tau pathology in the hippocampus of normal 
subjects is consistent with work by others (Heiko Braak, Thal, Ghebremedhin, & Del 
Tredici, 2011), and could potentially indicate either pre-clinical AD or early neurofibrillary 
tangle predominant dementia (NFTD). However, in the absence of clinical symptoms, it 
is not possible to make either diagnosis. These findings in normal controls are consistent 
with the idea that the activation of the UPR is due to the tau pathology and not the 
amyloid pathology.  
We reported strong genetic evidence that EIF2AK3 genotypes confer risk for 
PSP (Höglinger et al., 2011).  The strongest signal comes from single nucleotide 
polymorphism (SNP) rs7571971 that is within EIF2AK3.  There are several non-
synonymous coding polymorphisms in EIF2AK3 that track with risk and EIF2AK3 
appears to be the gene in this region involved in PSP.  However, another less likely but 
still plausible explanation is that PSP risk in this region comes from a regulatory element 
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that is intronic, within EIF2AK3, or in a close by intergenic region and that this element 
controls expression of another gene.  Also, the true PSP association could be from 
nearby genes (e.g. FOXI3 or RPIA) though this is less likely since the signal from SNPs 
in highlighting these genes are not as significant as SNPs within EIF2AK3.  The work 
presented here clearly demonstrates that in PSP, PERK is activated in a region-specific 
pattern that matches regions where neurodegeneration occurs.  Thus this functional 
evidence along with the strength of the genetic evidence indicates that EIF2AK3 and not 
an adjacent locus is the gene that confers risk for PSP.  
The SNP giving the strongest EIF2AK3 signal in the PSP GWAS (rs7571971) is 
intragenic in intron 2. This SNP is in strong disequilibrium with 3 EIF2AK3 exonic SNPs 
which are non-synonymous.  This relationship was predicted using 1,000 Genomes data 
and confirmed here in PSP subjects (Fig. 2.7).  These coding variants form two common 
(A and B) and one rare haplotype (D).  In PSP subjects, the low risk allele [C] at 
rs7571971 completely correlates with haplotypes A and D while the high risk rs7571971 
allele [T] completely correlates with haplotype B (Fig. 2.7).    
Work in lymphoblastoid cell lines (Liu et al., 2012) with different haplotypes show 
that expression of EIF2AK3 is not altered by these haplotypes.  However, when the 
PERK arm of the UPR is activated by thapsigargin, PERK from haplotype B homozygote 
cells is more active in phosphorylating eIF2α when compared to PERK from cells 
homozygous for haplotype A.  The haplotype that confers high risk for PSP produces the 
more active form of PERK, suggesting that activation of the UPR is pathogenic in PSP 
and not a protective response. This is consistent with observations in prion protein 
induced neurodegeneration.  Moreno et al., showed that during prion replication, 
synaptic failure and neuronal loss is temporally associated with UPR activation and 
inhibition of translation.  When translation is restored using over-expression of GADD34 
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to dephosphorylate eIF2α, survival of infected animals is prolonged.   In contrast, when 
the UPR is activated using salubrinal, survival is decreased (Moreno et al., 2012).   Both 
observations are consistent with activation of the PERK/eIF2α arm of the UPR 
enhancing neurodegeneration, as proposed here for PSP.   
The two low risk haplotypes (haplotype A, Ser-Arg-Ser; and haplotype B, Ser-
Gln-Ser) differ only at the middle amino acid, 166— this amino acid is unlikely to 
functionally influence PERK activation.  The low and high risk (Haplotype B, Cys-Gln-
Cys) haplotypes differ at both positions 166 and 704, and one or both may influence 
PERK activity.  Amino acid 166 is on the portion of PERK that is in the ER lumen and 
positioned where this protein senses mis-folded proteins.  Position 704 is on the 
cytoplasmc side of PERK, a segment of the protein that is phosphorylated when 
activated and that has the active site for phosphorylating eIF2α.  Additional work is 
needed to confirm that haplotype B PERK is the more active protein and to determine if 
mis-folded protein sensing or activation via auto phosphorylation is affected. 
Conclusions 
The PERK protein and its downstream effector eIF2α are phosphorylated in disease-
affected regions in both PSP and Alzheimer’s disease. A previous study using PSP 
samples described UPR activation primarily in the hippocampus, a brain region not 
affected in this disease (D. A. T. Nijholt et al., 2012). In contrast, we examined a large 
panel of brain areas (pons, medulla, midbrain, hippocampus, frontal cortex, and folia of 
the cerebellum) from PSP and AD cases as well as normal controls to show that this 
activation is disease-specific in its geographic distribution in the brain. In contrast to 
previous reports, we also found UPR activation in the hippocampus of a subset of our 
normal controls, a completely novel finding. This activation positively and significantly 
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correlated with both age and amount of tau pathology. This suggests that tau and UPR 
activation are linked. We also demonstrated a genetic association between an EIF2AK3 
protein coding haplotype and PSP, indicating that variation in the PERK protein affects 
PSP risk. 
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Table 2.1 Subject information. 
  n 
Avg 
Age of 
Onset 
Avg Age 
at Death 
Avg Disease 
Duration % Female Avg PMI 
Normal – age-
matched 
15 N/A 71.7(8.4) N/A 46.7 12.7(8.5) 
Normal – non 
age-matched 
12 N/A 54.5(24.9) N/A 66.7 9.1(3.4) 
Normal - total 27 N/A 64.0(19.4) N/A 56.7 11.1(6.9) 
PSP 17 66.8(5.8) 73.7(5.2) 6. 7(2.2) 64.7 11.7(6.0) 
AD 9 65.0(6.3) 75.8(5.1) 10. 8(3.4) 44.4 9.4(5.8) 
 
There were no significant differences between groups for average age at death 
(ANOVA, p = 0.33), post-mortem interval (ANOVA, p = 0.54), average age of onset (PSP 
and AD only, Student’s t-test, p = .45) or percent female (Chi Square, p = 0.89). Average 
disease duration for AD was significantly longer than for PSP (Student’s t-test, p = 
0.002). Standard deviations indicated inside parenthesis  
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Table 2.2 Anitbodies used. 
 
 
 
 
 
 Antigen Epitope Source Dilution 
Primary 
pPERK pThr981 Santa Cruz 1:4000 
peIF2α pSer51 Sigma-Aldrich 1:2000 
AT8 pSer202/pThr205 Thermo Scientific 1:7500 
Secondary 
goat α rabbit IgG biotin Vector Labs 1:1000 
goat α rabbit IgG AlexaFluor 488 Alexa 1:500 
goat α mouse IgG AlexaFluor 594 Alexa 1:500 
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Table 2.3  P-values for comparison of pPERK and pEIF2α immunoreactivity in 
PSP, AD, and normal controls for different brain regions. 
Comparison 
groups 
Pons Medulla Midbrain 
pPERK peIF2α pPERK peIF2α pPERK peIF2α 
AD vs. Normal 3.4E-5 0.0045 0.034 0.041 0.0026 0.0037 
PSP vs. AD 3.8E-4 0.00049 1.7E-4 0.028 4.0E-7 0.009 
PSP vs. Normal 3.8E-9 4.1E-5 6.1E-7 6.0E-6 6.0E-6 1.4E-4 
 
  
 
 
P-values are from a Fisher exact test.  “E” indicates “x 10^”. pPERK and peIF2α staining 
in PSP brainstem areas (pons, medulla, midbrain) were significantly greater than in AD 
or normal brainstem areas. AD brainstem areas had significantly more pPERK and 
peIF2α staining than normal brainstem areas. In contrast, primary AD-affected brain 
areas (hippocampus, frontal cortex) had significantly more pPERK and peIF2α staining 
than PSP or normal hippocampus and frontal cortex. There was no difference in staining 
between AD, PSP, or normal brains in the cerebellum 
 
Comparison 
groups 
Hippocampus Frontal Cortex Cerebellum 
pPERK peIF2α pPERK peIF2α pPERK peIF2α 
AD vs. Normal 0.0006 0.0042 4.1E-5 4.1E-5 0.4 1 
PSP vs. AD 0.000021 8.2E-5 1.6E-4 0.0049 0.5 1 
PSP vs. Normal 0.0034 0.073 0.0045 0.1 1 1 
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Table 2.4 PERK haplotypes. 
  
     
   
Alleles (%) 
 
rs867529-rs13045-rs1805165 Affected Amino Acids PSP (n=994) 
Haplotype A GCA Ser136-Arg166-Ser704 1233 (62.5) 
Haplotype B CTC Cys136-Gln166-Ala704 626 (31.7) 
Haplotype D GTA Ser136-Gln166-Ser704 113 (5.7) 
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Table 2.5 SNPs in high LD with rs7571971. 
SNP Gene 
Distance in base 
pairs from GWAS 
hit SNP RSquared DPrime Coordinate_HG18 
rs1805165 EIF2AK3 20460 0.889 1 88656006 
rs6739095 EIF2AK3 15287 0.886 0.96 88661179 
rs11898161 EIF2AK3 13703 0.925 1 88662763 
rs1913671 EIF2AK3 4532 0.886 0.96 88680998 
rs11681299 EIF2AK3 6381 0.889 1 88682847 
rs867529 EIF2AK3 17922 0.889 1 88694388 
rs6731022 EIF2AK3 21684 0.886 0.96 88698150 
rs11684404 EIF2AK3 29271 0.886 0.96 88705737 
rs11680549 EIF2AK3 30997 0.813 0.957 88707463 
rs6547787   34385 0.886 0.96 88710851 
rs1606803   37965 0.889 1 88714431 
rs62157778   38739 0.889 1 88715205 
rs13003510   46139 0.925 1 88722605 
rs13001657   51260 0.888 0.96 88727726 
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Table 2.S1 Individual Case Information 
Case Demographics 
Case 
# 
NPDx Sex 
Age at 
Death 
Disease 
Duration 
Post-Mortem Interval 
EIF2AK3 
haplotype 
1 PSP M 73 6 20.5 A/B 
2 PSP F 70 7 4.5 A/A 
3 PSP F 79 11 17 B/B 
4 PSP M 73 4 10.5   
5 PSP F 72 5 20   
6 PSP F 71 6 6.5 A/A 
7 PSP F 81 7 17 A/A 
8 PSP F 77 11 12.5 A/B 
9 PSP M 85 3 -   
10 PSP F 75 5 12 B/B 
11 PSP F 76 8 8 A/A 
12 PSP M 67 10 12 A/A 
13 PSP M 70 6 11 B/B 
14 PSP F 78 8 8 A/D 
15 PSP F 64 7 21 A/B 
16 PSP M 72 7 3.5 A/A 
17 PSP F 60 3 3 B/D 
18 Normal M 60 - 14 A/B 
19 Normal F 75 - 3.5 A/D 
20 Normal F 70 - 10.5 A/A 
21 Normal M 67 - 10.5   
22 Normal M 90 - 6 A/B 
23 Normal M 74 - 7.5   
24 Normal F 83 - 3 A/B 
25 Normal F 75 - 15   
26 Normal M 83 - 14.5 A/A 
* 27 Normal M 63   5   
* 28 Normal M 70   19   
* 29 Normal F 67   5.5   
 †* 30 Normal M 65 - 26   
 † 31 Normal F 89 - 7   
 † 32 Normal F 72 - 4   
 † 33 Normal F 51 - 5   
 † 34 Normal F 92 - 5   
 † 35 Normal F 68 - 32   
 † 36 Normal F 85 - 14   
 †* 37 Normal F 65 - 19 A/B 
 † 38 Normal F 56 - 12   
 † 39 Normal F 46 - 12   
 † 40 Normal M 47 - 11   
 † 41 Normal M 38 - 12   
 † 42 Normal M 16 - 8   
 † 43 Normal F 33 - 7   
 † 44 Normal M 29 - 12   
45 AD F 71 12 17   
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46 AD M 85 13 6.5   
47 AD F 72 17 12 A/A 
48 AD F 81 11 4 A/B 
49 AD M 70 10 5 A/A 
50 AD M 77 6 4 B/B 
51 AD M 74 12 7.5 A/B 
52 AD M 73 10 9 A/B 
53 AD F 79 6 20 A/A 
 
Neuropathological diagnosis, sex, age at death, disease duration, post-mortem interval, 
Braak stage, and hippocampal Aβ amyloid plaque score for all cases and controls used 
† = hippocampus only  
* = pons, cerebellum and/or hippocampus only. 
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Figure 2.1 pPERK is activated in PSP, AD, and normal brain. a. Example of a cell 
with pPERK immunoreactive puncta in the pons of a PSP case. b-d. Representative 
fields showing pPERK staining of pons, hippocampus, and cerebellum in normal, PSP, 
and AD cases. Scale bars are 50µm unless otherwise indicated 
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Figure 2.2 peIF2α is activated in PSP, AD, and normal brain. a. Example of a cell 
with peIF2α puncta in the pons of a PSP case. b-d. Representative fields from peIF2α 
staining of pons, hippocampus, and cerebellum in normal, PSP and AD cases. Scale 
bars are 50µm unless otherwise indicated 
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Figure 2.3 Frequency of pPERK staining scores in PSP, AD, and normal brain. 
Distribution of pPERK staining scores. +++ = widespread activation, ++ = moderate 
activation, + = diffuse activation, R = rare activation, - = no activation. Y-axis indicates 
number of cases with a particular pPERK staining score. All P-values obtained using 
Fisher exact test. a-c. PSP cases had the strongest pPERK staining in the pons (PSP 
vs. Normal: p = 3.8E-9) and the medulla (PSP vs. Normal: p = 6.1E-7), as well as 
moderate staining in the midbrain (PSP vs. Normal: p = 6.0E-6) which was affected in all 
PSP cases. d-e. AD cases had the strongest pPERK staining in the hippocampus (AD 
vs. Normal: p =  0.0006) and moderate staining in the frontal cortex (AD vs. Normal: p = 
4.1E-5) both of which were affected in AD. f. No cases had significant pPERK staining in 
the cerebellum 
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Figure 2.4 Frequency of peIF2α staining scores in PSP, AD, and normal brain. 
Distribution of peIF2α staining scores. +++ = widespread activation, ++ = moderate 
activation, + = diffuse activation, R = rare activation, - = no activation. Y-axis indicates 
number of cases with a particular peIF2α staining score. All P-values obtained using 
Fisher exact test. a-c. PSP cases had the strongest peIF2α staining in the pons (PSP vs. 
Normal: p = 4.1E-5) and the medulla (PSP vs. Normal: p = 6.0E-6), as well as moderate 
staining in the midbrain (PSP vs. Normal: p = 0.00041) which was affected in all PSP 
cases. d-e. AD cases had the strongest peIF2α staining in the hippocampus (AD vs. 
Normal: p = 0.0042) and moderate staining in the frontal cortex (AD vs. Normal: p = 
4.1E-5) both of which were affected in AD. f. No cases had significant peIF2α staining in 
the cerebellum 
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Figure 2.5 Hyperphosphorylated tau and pPERK partially co-localize in PSP pons 
and AD hippocampus. a. Example of a neuron co-stained for htau (red) and pPERK 
(green). Tau staining is widespread and diffuse. pPERK staining is punctate and 
localized to the soma and proximal neurites. b. pPERK staining occurred mostly in cells 
with diffuse, non-fibrillar htau staining. Cells with dense, fibrillar htau staining did not 
stain for activated PERK (*). c. In PSP pons, most pPERK positive cells also stained for 
htau (72%), whereas fewer than half of htau stained cells (43%) also stained positive for 
pPERK. d. htau and pPERK staining overlapped very little in AD hippocampus (14% and 
20%). Scale bars are 50µm unless otherwise indicated 
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Figure 2.6 Severity of PERK activation in normal hippocampus correlates with age 
and tau pathology. a. Plot of pPERK staining score (X-axis) versus subject age at 
death (Y-axis). Each diamond represents one normal subject. Some individuals both 
young and old were negative for pPERK staining. Of those that stained positive for 
pPERK (including those showing rare through +++ levels of immunoreactivity), older 
individuals tended to have more severe pPERK staining scores. b. Frequency table 
plotting htau score against pPERK staining score in normal hippocampus. Htau score 
and pPERK score were positively correlated (Spearman R: .7523; p=0.0002). The higher 
the htau score of an individual hippocampus, the higher the pPERK staining score 
tended to be. Htau scores were obtained from the CNDR Integrated Neurodegenerative 
Disease Database[42] using antibody PHF-1   
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Figure 2.7 Comparison of PERK haplotype with GWAS risk allele. A GWAS for PSP 
identified a risk locus on chromosome 2 (rs7571971). The common, low risk allele at this 
locus is cytosine (C) and the PSP risk allele is thymine (T) [10]. Among individuals 
homozygous for C at this locus, all harbor PERK haplotype A or D in some combination. 
Individuals heterozygous (C/T) at this locus were heterozygous for haplotypes A, B, 
and/or D. Individuals homozygous for T at the GWAS risk locus were always 
homozygous for PERK haplotype B. This demonstrates that one of the two amino acid 
changes conferred by the B PERK haplotype that are not shared by the D haplotype 
may be responsible for the PSP risk evident on Chr. 2 
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Figure 2.S1 Scoring system examples. Representative fields from brain areas that 
scored “-“ (negative), “R” (rare), “+” (mild staining), “++” (moderate staining), and “+++” 
(heavy staining), along with scoring criteria. 
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ABSTRACT 
EIF2AK3, the gene that codes for the PERK protein, is associated with PSP disease 
risk. There are two common protein coding variants of PERK, HapA and HapB, which 
differ by three amino acids. Recent work indicates HapB PERK has more kinase activity 
in response to thapsigargin treatment than does HapA in human β-lymphocytes (Liu et 
al., 2012). This project had two goals: 1) replicate and expand upon previous findings in 
β-lymphocytes and 2) determine which of the three amino acid coding changes is 
responsible for the difference in PERK activity between HapA and HapB. This work 
confirms that β-lymphocytes expressing HapB PERK show more eIF2α phosphorylation 
than those expressing HapA. Paradoxically, HapB PERK cells also show less 
phosphorylated PERK. These findings were echoed in mouse embryonic fibroblasts 
expressing PERK variant constructs. Further work exploring the functional differences 
between PERK variants is warranted. 
 
INTRODUCTION 
The PERK protein is part of the cell’s unfolded protein response (UPR). The 
PERK arm of the UPR acts primarily on translation. When PERK is activated (thus 
becoming phospho-PERK, or pPERK), a kinase domain on the cytosolic side of the 
protein phosphorylates eukaryotic translation initiation factor 2α (eIF2α). peIF2α then 
acts at the ribosome to slow down general translation initiation and promote translation 
of ATF4 (Ron & Walter, 2007). ATF4 promotes the transcription of genes that enhance 
import of amino acids and protect against oxidative stress (Harding et al., 2003). 
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Three single nucleotide polymorphisms (SNPs) that confer coding changes to the 
PERK protein are linked with disease risk for progressive supranuclear palsy (PSP; 
Stutzbach et al., 2013). The more common coding variant, “Haplotype A,” is lower risk, 
while the less common variant “Haplotype B” is higher risk (for amino acid sequences, 
see Table 3.2). Work in human β-lymphoblastoid cell lines shows that the Haplotype B 
form of PERK is more active in response to treatment with the UPR-inducing drug 
thapsigargin (Liu et al., 2012). 
The goal of this thesis project is to determine what role PERK and the UPR play 
in PSP pathogenesis. I have done this by determining the distribution of activated PERK 
in the post-mortem PSP-affected brain, examining the association between pPERK and 
tau, and analyzing the genetic association between common variations to the PERK 
protein and PSP (Stutzbach et al., 2013). The present analysis aims to expand on those 
findings by determining the biological effects of PERK protein coding variants on PERK 
function.  
MATERIALS AND METHODS 
Generation of PERK constructs 
Human PERK cDNA clones were obtained from Transomic Technologies 
(Huntsville, AL; Fig 3.1A). To create PERK variants, we performed site-directed 
mutagenesis using the QuikChange Multi kit (Agilent Technologies, Santa Clara, CA). 
For primers, see Table 3.1. All PERK variants were sequence-confirmed using CMV 
primers (pTCN promoter for PERK insert; Fig. 3.1A and 3.1B). 
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Cell Culture 
We obtained human β-lymphocyte cell lines from Coriell Cell Repository 
(Camden, NJ). Cell lines expressing PERK haplotype A were NA06985, NA06991, 
NA06993, NA07029, NA07055; cell lines expressing PERK haplotype B were NA07348, 
NA07357, NA10835, NA11993, and NA12249. We cultured β-lymphocytes in RPMI-
1640 media (Corning Cellgro, Manassas, VA) supplemented with 15% fetal bovine 
serum (FBS), 1% L-glutamine, and 1% Pen Strep antibiotic. Drug treated cells were 
dosed with 0.1μM thapsigargin (reconstituted in DMSO) for 30 minutes.  
Mouse embryonic fibroblasts (MEFs) negative for the PERK protein were the 
generous gift of the Constantinos Koumenis laboratory (University of Pennsylvania, 
Philadelphia, PA) and originated from PERK knockout mice generated by the Douglas R. 
Cavener laboratory (Pennsylvania State University, State College, PA). PERK knockout 
was carried out using Cre-Lox recombination as described in Zhang P. et al (2002).  
MEFs were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% FBS, 1% L-glutamine, and 1% Pen-strep. PERK constructs and 
the pTCN empty vector were tranfected into MEFs using Lipofectamine LTX with PLUS 
reagent (Invitrogen, Carlsbad, CA) and cells were harvested 24 hours later. Drug-treated 
cells were dosed with 0.1μM thapsigargin (reconstituted in DMSO) for 75 minutes before 
harvest. 
At harvest, all cells were washed twice with 1x PBS then (with the exception of 
cells harvested for nuclear protein isolation)  lysed using cell lysis buffer formulated by 
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the David Ron laboratory in Cambridge, UK 
(http://ron.cimr.cam.ac.uk/protocols/IP.IMMUNOBLOT.html), consisting of 1% TritonX 
100, 150mM NaCl, 20mM Hepes pH 7.5, 10% glycerol, 1mM EDTA, 1x Halt 
phosphatase inhibitor (Life Technologies, Thermo-Fisher Scientific, Rockville, IL), and 
cOmplete protease inhibitor cocktail (Roche, Basel, Switzerland). Cells targeted for 
nuclear protein isolation were harvested using the Biovision cell fractionation kit 
(Milpitas, CA) according to manufacturer protocol. Cells harvested for PERK expression 
analysis were lysed in TRI reagent (Ambion, Thermo Scientific, Rockford, IL) and RNA 
isolated according to manufacturer protocol. Protein concentration for all cell lysates was 
calculated using the Pierce BCA assay (Thermo Scientific, Rockford, IL) according to 
manufacturer protocol.  
PERK expression analysis 
PERK null MEFs were transfected with 2.5 ug PERK cDNA using Lipofectamine 
LTX with PLUS reagent (Invitrogen, Carlsbad, CA) and cells were harvested 24 hours 
later using Tri reagent (Ambion, Thermo Scientific, Rockford, IL). RNA was isolated 
according to TRI reagent manufacturer protocol. RNA from PERK-transfected cells was 
reverse-transcribed into cDNA using High Capacity Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA) and transcript levels quantified using qPCR TaqMan 
Assays designed to detect PERK (Hs00178128_m1 and Hs00984006_m1; Applied 
Biosystems, Foster City, CA) according to manufacturer protocol (50o C 2min, 95oC 
10min, 40x: 95oC 15sec, 60oC 1min). PCR results were quantified and analyzed using 
the ∆∆CT (cycle threshold) relative quantification method in Expression Suite software 
(Applied Biosystems, Foster City, CA). Endogenous control was Hprt 
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(Mm01545399_m1). Relative Quantification (RQ) values (fold change compared to 
calibrator sample [HapA]) greater than 2 or less than 0.5 were considered significant 
(https://genomique.iric.ca/resources/files/How_to_deal_with_qPCR_results.pdf). 
Western blotting 
Cell lysates were combined with Lane Marking Reducing Sample Buffer (Thermo 
Scientific, Rockford, IL) and boiled for 10 minutes before loading onto 4-20% Tris-HCL 
Criterion gels (BioRad, Hercules, CA). Proteins were transferred to PVDF membrane, 
blocked in 5% non-fat milk for one hour or 5% bovine serum albumin (for peIF2α 
detection only) for one hour, then incubated in primary antibody overnight. Blots were 
washed in Tris-buffered saline with 1% Triton-X 100 (Roche Boehringer Mannheim, 
Basel, Switzerland; TBS-T), incubated in secondary antibody for two hours, washed 
again, then incubated in Luminata Forte or Crescendo Western substrate (Millipore, 
Bilerica, MA) for five minutes. Each blot was exposed to film for a variable length of time 
and developed in a Xomat 200A Professional developer (Kodak, Rochester, NY). For 
antibody sources and concentrations, see Table 3.2. 
Western blot analysis 
Western bands were quantified using ImageJ image analysis software 
(http://imagej.nih.gov/ij/). Each band was normalized first to its corresponding loading 
control: total eiF2α was the loading control for peIF2α, and a 125 kDA protein band from 
a Fast Green protein stain was the loading control for total PERK, pPERK, and ATF4. In 
the MEF experiment, each pPERK, ATF4, and peIF2α band was then normalized to its 
corresponding total PERK band to correct for variability in PERK expression. All values 
reported represent normalized relative density values for each band. 
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RESULTS 
Thapsigargin treatment  
To determine the optimal treatment duration for thapsigargin treatment, I 
performed a time course analysis of eIF2α phosphorylation in PERK null (P -/-) MEFs 
expressing human PERK. I transfected cells with HapA PERK and treated with 0.1μM 
thapsigargin (tg) for 5, 15, 30, 45, 75, 90, 105, and 120 minutes before harvest. peIF2α 
levels increased steadily with longer treatment times, peaking at 75 minutes and 
remaining strong through 105 minutes (Fig. 3.2 A-B). For all subsequent experiments, 
treatment time in P -/- MEFs expressing human PERK constructs was 75 minutes. 
PERK expression analysis 
To confirm uniform transfection and expression, I transfected P-/- MEFs with 
each PERK construct and harvested RNA at 24 and 48 hours to perform qPCR. The 
results of two Taqman Gene Expression Assays (Life Technologies) for PERK 
demonstrated no significant differences in PERK transcript level between constructs (for 
construct information, see Fig. 3.1 and Table 3.2); RQ values were less than 2 and 
greater than 0.5 (Fig. 3.3; see Methods section). However, PERK transcript levels in 
general were higher at 24 hours post-transfection (ptf) than at 48 hours ptf. Therefore, 
cells were harvested at 24 hours ptf for all subsequent PERK transfection experiments. 
PERK haplotype comparison in human β-lymphocytes 
Liu et al. (2012) showed that human β-lymphocytes (β-L) homozygous for PERK 
HapB have higher levels of eIF2α phosphorylation in response to tg treatment than β-Ls 
homozygous for haplotype A. In order to replicate and expand upon this finding, I 
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harvested cell lysates from four β-L lines homozygous for HapA and four homozygous 
for HapB, with and without 0.1μM tg treatment (30 min). All cell lines were sequence-
confirmed homozygotes for HapA or HapB (see Methods for cell line information). I then 
probed for total PERK, pPERK, total eIF2α, peIF2α, and β-actin (loading control) by 
Western blot (Fig. 3.4A). 
Total PERK levels did not vary between HapA and HapB, with or without tg 
treatment (Fig. 3.4B). However, phosphorylated PERK (pPERK) levels were significantly 
lower in HapB lines in comparison to HapA lines in both untreated and tg treated cells 
(Fig. 3.4C; for total PERK and pPERK antibody information, see Table 3.3). This is in 
contrast to significantly higher peIF2α levels in HapB lines in comparison to HapA lines 
(Fig. 3.4D). While these peIF2α findings replicate the results from Liu et al (2012), this 
decrease in pPERK in HapB is a novel finding. This indicates that the increase in peIF2α 
levels may be independent of PERK’s autophosphorylation status.  
There are a number of potential explanations for this seemingly contradictory 
finding. First, the changes to the PERK protein that make up HapB PERK may interfere 
with the pPERK antibody epitope (Thr982), indicating a difference in detection of pPERK 
rather than a difference in actual pPERK levels. However, it is also possible that the 
amino acid differences between HapA and HapB on the N-terminal end of the protein 
(S136C and R166Q) act to promote and stabilize PERK dimerization (thereby increasing 
the likelihood of eIF2α kinase activity), while the change to the C-terminal, cytoplasmic 
end of PERK (S704A, the change nearest to a protein kinase domain) decreases the 
likelihood of PERK transautophosphorylation. Further investigation into how the protein 
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coding differences between HapA and HapB affect post-translational modifications 
would be needed to determine which of these explanations is more likely.  
Another caveat to this finding is that the lower pPERK levels for HapB +tg seem 
to be driven by only half of the Hap B cell lines (compare the last four lanes for pPERK in 
Fig. 3.4A). Thus, there may be additional factors at work in these cell lines and further 
study of additional HapB homozygotes would be necessary to confirm and expand upon 
this finding. 
PERK variant comparison in P-/- MEFs: 
To determine which of the three protein coding variants that make up HapB is 
responsible for the difference in eIF2α phosphorylation between HapA and HapB, I 
created several PERK constructs with the goal of expressing each in PERK knockout 
cells and measuring activity. These PERK constructs are listed in Table 3.2. 
I expressed each of these constructs in P-/- MEFs obtained from the Koumenis 
laboratory ( Zhang et al., 2002)and harvested cell lysates 24 hours post-transfection 
(ptf). I then probed for total PERK, pPERK, total eIF2α, peIF2α, ATF4 (ATF4 probed in 
nuclear lysates only), and β-actin by Western blot (Fig. 3.5, Fig. 3.10). I then performed 
relative quantification analysis using ImageJ software (http://imagej.nih.gov) and 
normalized each Western band first to a loading control (a band at approximately 125 
kDa from a fast green protein stain) and then to PERK expression for that run. 
Quantifications in Figures 3.6-3.9 represent the mean values from 4 independent 
replicates of this experiment. To determine statistical significance, I performed unpaired 
t-tests between each “test” construct (HapB, 136C, 166Q, 704A) and HapA for all 
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measures. I also performed paired t-tests within each construct to compare expression 
levels with and without thapsigargin treatment. 
PERK levels were not statistically different between constructs in the absence of 
tg treatment (Fig. 3.6A). However, tg treatment resulted in a dip in total PERK levels in 
HapB (p=0.02) and 136C (p=.05) in comparison to HapA (Fig 3.6B). Because total 
PERK levels for both HapB and 136C also tended to be lower in the absence of tg 
treatment, these differences were likely just slightly magnified in the drug treatment 
condition. Total PERK levels did not significantly change within each construct after tg 
treatment (Fig 3.6C). 
pPERK levels for HapB, 136C, 166Q, and 704A were not statistically different 
from Hap A in the absence of tg treatment (Fig. 3.7A). However, pPERK levels were 
slightly, albeit significantly, lower in 704A relative to HapA (p=.01; Fig. 3.7B). pPERK for 
all constructs increased significantly with tg treatment (all p-values < 0.05; Fig. 3.7C). To 
determine whether the magnitude of response to tg treatment differed between each 
construct and HapA, I calculated the ratio of tg treated to untreated for pPERK levels. 
The ratio of tg treated to untreated for each construct was not significantly different from 
the tg treated to untreated for HapA, though tg treatment tended to have a greater 
magnitude of effect on HapB (Fig 3.7D). 
peIF2α levels for HapB, 136C, 166Q, and 704A were not statistically different 
from HapA with or without tg treatment, and tended to be variable (Fig. 3.8A). HapB 
peIF2α levels did tend to be slightly higher than those of HapA, but this difference was 
nonsignificant (p=0.253; Fig 3.8B). peIF2α for all constructs did not increase significantly 
with tg treatment  (all p-values > 0.05), again likely due to variability (Fig 3.8C). Likewise, 
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the ratio of tg treated to untreated for each construct was not significantly different from 
the tg treated to untreated for HapA (Fig. 3.8D). 
ATF4 levels for HapB, 136C, 166Q, and 704A were not statistically different from 
HapA with or without tg treatment. However, as with peIF2α, HapB levels of ATF4 
tended to be highest and HapA levels lowest (tg treatment condition), with the individual 
amino acid variants showing an intermediate level (Fig. 3.9A-B). ATF4 for all constructs 
did not increase significantly with tg treatment (all p-values > 0.05; Fig 3.9C), though this 
may, again, be due to variability. The ratio of tg treated to untreated for each construct 
was not significantly different from the tg treated to untreated for HapA (Fig. 3.9D). 
DISCUSSION 
In this study, I was able to replicate the finding from Liu et al (2012) that human 
β-lymphocytes homozygous for PERK haplotype B demonstrate higher levels of eIF2α 
phosphorylation in response to tg treatment than do β-Ls homozygous for PERK 
haplotype A. I also found that HapB B-Ls showed lower pPERK levels in response to the 
same treatment. Bearing in mind the newness of the pPERK antibody and the potential 
for this antibody to have a weaker affinity for HapB PERK than HapA PERK, this finding 
seems ripe for a follow-up study with a larger sample size comparing the two haplotypes. 
If this effect can be replicated and expanded, the next step could be to examine how the 
HapB version of the protein differs from HapA in either structure (perhaps a difference in 
disulfide bonding conferred by the 136 S->C variation) or in post-translational 
modifications (notably, potential phosphorylation sites S136 and S704, which are ablated 
by HapB).  
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Though PERK null MEFs transiently expressing different variants of the PERK 
protein (HapA, HapB, 136C, 166Q, 704A) largely did not statistically differ from one 
another in pPERK, peIF2α, or ATF4 levels, these results suggest a trend toward HapB-
expressing cells having a stronger response to tg treatment. HapB expressing cells 
showed a bigger difference between baseline levels of pPERK, peIF2α, and ATF4 and 
these same levels after tg treatment. This difference in the magnitude of response to 
thapsigargin between HapA and HapB echoes the findings in β-lymphocytes discussed 
above. Interestingly, MEFs expressing the single amino-acid variant PERK constructs 
may have an “intermediate” effect on thapsigargin response—this is suggested by ATF4 
levels quantified in Figure 8. Note that ATF is highest for HapB +tg, followed by 136C 
+tg and then 166Q +tg. This dampening of the effect of HapB in the single amino acid 
variant constructs may indicate that these protein coding variations act synergistically to 
change PERK’s biological activity. However, as these results were not statistically 
significant, further study is needed (perhaps in a less variable model) to confirm this 
finding. Additionally, further work should examine the effect on PERK function of 
pseudophosphorylation at position 136 and position 704 (see PERK construct creation 
breakdown under “PERK variant comparison in P-/- MEFs” above). Another PERK 
construct that would be valuable in this future analysis is a 136A variant—this construct 
would negate possible modifications at that site present in HapA (potential S136 
phosphorylation) and HapB (potential disulfide bond formation at 136C). 
Further study of PERK variants and both their differences in activity and their 
effect on disease pathogenesis and progression seems warranted. Our previous work 
demonstrated that PERK HapB is associated with risk for PSP, a neurodegenerative 
disease. This work also showed that PERK is activated in post-mortem brain regions 
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affected by PSP and Alzheimer’s disease. Other studies have shown PERK activation in 
the brain in Parkinson’s disease (Hoozemans et al. 2007), ALS (Atkin et al. 2001, Wang 
et al. 2010), AD (Hoozemans et al 2009), multiple system atrophy (Makioka et al. 2010) 
and other tauopathies (Nijholt et al. 2012). Therefore, it may be that differences in PERK 
function are magnified in the brain or that neurons are more sensitive to these 
differences.  
Further study into functional variations of PERK should also examine how post-
translational modifications affect differences in activity between HapA and HapB. HapA 
contains two serines (S136 and S704) not present in HapB. Phosphorylation at either of 
these sites could potentially affect activity. Thus, future studies could incorporate PERK 
constructs pseudophosphorylated at these sites (136E and 704E). Conversely, this work 
could also examine activity of PERK that is unphosphorylatable and incapable of 
disulfide bonding at residue 136 (136A). Another way to approach this question would be 
to determine by mass spectrometry whether either of these serines are phosphorylated 
on endogenously expressed HapA PERK, either at baseline or in response to stress. 
It may be that PERK -/- MEFs are not an ideal model to study PERK variation 
and its contribution to disease pathogenesis. Because PERK plays a role in 
neurodegeneration, future work could benefit from using neuronal cultures to explore this 
question. The specialized functions of neurons and their heavy reliance on protein 
translation may make them especially vulnerable to sustained PERK activation. Though 
there are, as of yet, no neuronal cell culture models of tau aggregation (Guo & Lee, 
2014), this type of system would be ideal for studying the interaction between PERK 
variation and tau pathogenesis. 
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Table 3.1 Primers for Site-Directed Mutagenesis 
Primer Name Primer Sequence (5' to 3') 
166Q: g497a 5'-ctcttccagtgggaccaagaccgtgaaagcatg-3' 
136C: c407g 5'-atgtgggatccggttgcttggtgtcatccag-3' 
704A: t2110g_antisense 5'-gatttcaatatgttcttttgtagcgaaaggatccattctgcgtatt-3' 
136C: c407g_antisense 5'-ctggatgacaccaagcaaccggatcccacat-3' 
704A: t2110g 5'-aatacgcagaatggatcctttcgctacaaaagaacatattgaaatc-3' 
166Q: g497a_antisense 5'-catgctttcacggtcttggtcccactggaagag-3' 
Additional Primers: Phosphomimetic 
t406g_c407a_c408g 5'-atttggatgtgggatccggtgagttggtgtcatccagccttag-3' 
t2110g_c2111a_t2112g 5'-
cagttaaaatacgcagaatggatcctttcgagacaaaagaacatattgaaat
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catagctc-3' 
t406g_c407a_c408g_antisense 5'-ctaaggctggatgacaccaactcaccggatcccacatccaaat-3' 
t2110g_c2111a_t2112g_antisense 
5'-
gagctatgatttcaatatgttcttttgtctcgaaaggatccattctgcgtattttaact
g-3' 
 
Table 3.2 PERK Constructs 
Construct Name Amino Acid at position 
136-166-704 
PERK Haplotype A S136-R166-S704 
PERK Haplotype B C136-Q166-A704 
PERK 136C C136-R166-S704 
PERK 166Q S136-Q166-S704 
PERK 704A S136-R166-A704 
PERK 136E (phospho-mimetic) E136-R166-S704 
PERK 704E (phospho-mimetic) S136-R166-E704 
 
 
 
 
 
 
 
 
 
 
Table 3.3 Antibodies 
Antibody Name Company Dilution Origin 
PERK C33E10 Cell Signaling Technologies 1:500 Rabbit 
pPERK Eli Lilly 1:1000 Rabbit 
eIF2α L57A5 Cell Signaling Technologies 1:1000 Mouse 
peIF2α S51 Cell Signaling Technologies 1:250 Rabbit 
ATF4 (Creb-2) SC-200 Santa Cruz 1:1000 Rabbit 
β-actin Cell Signaling Technologies 1:50,000 Mouse 
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A  
Figure 3.1. PERK construct vector map and schematic. A. Human PERK cDNA 
clones were obtained from Transomic Technologies (Huntsville, AL; vector: pTCN; 
image obtained from www.transomic.com). B. To create PERK variants, we 
performed site-directed mutagenesis using the QuikChange Multi kit (Agilent 
Technologies, Santa Clara, CA) at three sites: rs867529 (S136C), rs13045 (R166Q), 
and rs1805165 (S704A). Together, these three variations make up “Haplotype B” 
(HapB). We mutated PERK at all three HapB sites individually to determine whether 
single amino acid variations affect PERK function. For a full list of PERK variant 
constructs, see Table 3.2. SNP rs7571971, shown here in red, is associated with 
PSP risk (REF) and is in LD with all three HapB SNPs. 
A 
B 
R166Q 
S136C S704A 
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 Figure 3.2. Thapsigargin treatment time course for peIF2α. A. Western blot bands of 
total eIF2α and peIF2α from PERK null MEFs expressing PERK HapA construct (Table 
3.2). Phosphorylation of eIF2α peaked at 75 min/tg treatment. B. Quantification of 
Western blots in A. Relative density for each peIF2α band normalized to corresponding 
total eIF2α band.  
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Figure 3.3. Relative quantification of PERK expression by qPCR. Each PERK 
construct (B: HapB, A: HapA, 136: 136C, 166: 166Q, 704: 704A, pCTN: empty vector; 
see Table 3.2) demonstrated less than twofold change in expression (relative 
quantification score [RQ] of greater than 2 or less than 0.5). PERK constructs were 
transfected into PERK null (-/-) MEFs and RNA harvested 24 hours later. PERK 
expression detected by Taqman Gene Expression Assays (Life Technologies) designed 
to detect PERK transcripts (PERK 1 and PERK 2). Endogenous control: HPRT1. 
 
 
 
 
 
 
 
   
67 
 
 
 
 
 
 
 
 
 
 
 
A B
A
 +
tg
B
 +
tg
0 .0
0 .5
1 .0
1 .5
P E R K
P E R K  h a p lo ty p e
r
e
la
ti
v
e
 d
e
n
s
it
y
A B
A
 +
tg
B
 +
tg
0 .0
0 .5
1 .0
1 .5
2 .0
p e if2 
P E R K  h a p lo ty p e
r
e
la
ti
v
e
 d
e
n
s
it
y
*
A 
B 
p=.02 
p=.02 
p=.03 
D 
C 
A B
A
 +
tg
B
 +
tg
0 .0
0 .1
0 .2
0 .3
0 .4
p P E R K
P E R K  h a p lo ty p e
r
e
la
ti
v
e
 d
e
n
s
it
y
*
*
D 
   
68 
 
Figure 3.4. Human β-lymphocytes endogenously expressing PERK haplotype A 
and PERK haplotype B. A. Western blots comparing levels of total PERK, pPERK, 
peIF2α, and total eIF2α between HapA and HapB, with and without 0.1μM tg treatment 
(30min). Band quantifications were normalized to fast greenCell lines expressing PERK 
haplotype A were NA06985, NA06991, NA06993, NA07029 (lanes 1-4 and 9-12, 
respectively; cell lines expressing PERK haplotype B were NA07348, NA07357, 
NA10835, NA11993 (lanes 5-8 and 13-16, respectively). Each lane represents one cell 
line homozygous for HapA (n=4) or HapB (n=4). Loading controls: fast green and β-
actin. B-D. Quantification of Western blots in A. B. PERK levels did not vary significantly 
between haplotypes or with drug treatment. C. peIF2α levels were significantly higher in 
HapB cells after tg treatment. D. pPERK levels were significantly lower in HapB cells 
with or without tg treatment. *p<0.05.  Error bars represent standard deviation. 
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Figure 3.5 Western blots of PERK -/- MEFS expressing human PERK constructs. 
A. Western blot loaded for visual comparison between constructs. B. Western blot 
loaded for visual comparison between each construct with and without tg treatment. P-/-
=PERK null MEFs, pTCN=empty vector. For quantification, see Fig 3.6-3.9. 
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Figure 3.6 Quantification of PERK from Western blots.  A-B. Comparison of PERK 
levels between constructs. P-values are comparisons between each construct and 
HapA. A. PERK levels were not statistically different between constructs in the absence 
of tg treatment. B. Tg treatment resulted in a dip in total PERK levels in HapB (p=0.02) 
and 136C (p=.05) in comparison to HapA. C. Comparison of PERK levels with and 
without tg treatment for each construct. P-values are comparisons within each construct 
with and without tg. PERK levels did not significantly change within each construct with 
tg treatment. All PERK bands normalized to fast green protein bands (loading control). 
Error bars represent standard deviation. 
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Figure 3.7 Quantification of pPERK from Western blots. A-B. Comparison of pPERK 
levels between constructs. P-values are comparisons between each construct and 
HapA. A. pPERK levels were not statistically different between constructs in the absence 
of tg treatment. B. pPERK levels were significantly lower in 704A relative to HapA 
(p=.01). C. Comparison of pPERK levels with and without tg treatment for each 
construct. P-values are comparisons within each construct with and without tg. pPERK 
for all constructs increased significantly with tg treatment (all p-values < 0.05). D. The 
ratio of tg treated to untreated for each construct was not significantly different from the 
tg treated to untreated for HapA, though tg treatment tended to have a greater 
magnitude of effect on HapB. Error bars represent standard deviation. 
 
 
 
 
 
 
 
 
 
 
 
D 
   
73 
 
 
 
H
a
p
A
 +
tg
H
a
p
B
 +
tg
1
3
6
C
 +
tg
1
6
6
Q
 +
tg
7
0
4
A
 +
tg
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
p e IF 2  + tg
P E R K  v a r ia n t
r
e
la
ti
v
e
 d
e
n
s
it
y
 
H
a
p
A
H
a
p
B
1
3
6
C
1
6
6
Q
7
0
4
A
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
p e IF 2  th a p
P E R K  v a r ia n t
r
e
la
ti
v
e
 d
e
n
s
it
y
U n tre a ted
+ th a p s ig a rg in
 
H
a
p
A
H
a
p
B
1
3
6
C
1
6
6
Q
7
0
4
A
0 .0
0 .5
1 .0
1 .5
p e IF 2
P E R K  v a r ia n t
r
e
la
ti
v
e
 d
e
n
s
it
y
A B 
C peIF2 +tg 
   
74 
 
H
a
p
A
H
a
p
B
1
3
6
C
1
6
6
Q
7
0
4
A
0
1
2
3
4
5
p e IF 2  ra t io
P E R K  v a r ia n t
tg
 t
r
e
a
te
d
:u
n
tr
e
a
te
d
 
Figure 3.8 Quantification of peIF2α from Western blots. A-B. Comparison of peIF2α 
levels between constructs. P-values are comparisons between each construct and 
HapA. A. peIF2α levels were not statistically different between constructs with or B. 
without tg treatment. C. Comparison of peIF2α levels with and without tg treatment for 
each construct. P-values are comparisons within each construct with and without tg. 
peIF2α for all constructs did not increase significantly with tg treatment  (all p-values > 
0.05). D. The ratio of tg treated to untreated for each construct was not significantly 
different from the tg treated to untreated for HapA. Error bars represent standard 
deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
D 
   
75 
 
 
 
 
H
a
p
A
 +
tg
H
a
p
B
 +
tg
1
3
6
C
 +
tg
1
6
6
Q
 +
tg
7
0
4
A
 +
tg
0
2
4
6
A T F 4  + tg
P E R K  v a r ia n t
r
e
la
ti
v
e
 d
e
n
s
it
y
 
H
a
p
A
H
a
p
B
1
3
6
C
1
6
6
Q
7
0
4
A
0
2
4
6
A T F 4  th a p
P E R K  v a r ia n t
r
e
la
ti
v
e
 d
e
n
s
it
y
U n tre a ted
+ th a p s ig a rg in
 
H
a
p
A
H
a
p
B
1
3
6
C
1
6
6
Q
7
0
4
A
0 .0
0 .5
1 .0
1 .5
A T F 4
P E R K  v a r ia n t
r
e
la
ti
v
e
 d
e
n
s
it
y
A B 
C  +tg 
ATF4 +tg 
   
76 
 
H
a
p
A
H
a
p
B
1
3
6
C
1
6
6
Q
7
0
4
A
0
5
1 0
1 5
2 0
A T F 4  ra t io
P E R K  v a r ia n t
tg
 t
r
e
a
te
d
:u
n
tr
e
a
te
d
 
 
Figure 3.9 Quantification of ATF4 from Western blots. A-B. Comparison of ATF4 
levels between constructs. P-values are comparisons between each construct and 
HapA. A. ATF4 levels were not statistically different between constructs with or B. 
without tg treatment. C. Comparison of ATF4 levels with and without tg treatment for 
each construct. P-values are comparisons within each construct with and without tg. 
ATF4 for all constructs did not increase significantly with tg treatment (all p-values > 
0.05). D. The ratio of tg treated to untreated for each construct was not significantly 
different from the tg treated to untreated for HapA. Error bars represent standard 
deviation. 
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Figure 3.10. Additional Western blot included in preceding analysis. P-/-=PERK null 
MEFs, pTCN=empty vector. For quantification, see Figures 3.6-3.9. 
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CHAPTER 4: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
Neurodegenerative diseases represent a major health crisis in the United States 
and around the world. By the year 2050, an estimated 16 million older Americans will 
suffer from Alzheimer’s disease (AD) at a cost of 1.2 trillion dollars in direct care 
(Alzheimer’s Association, www.alz.org). Finding treatments that halt or delay disease 
progression will be a major public health priority in the years to come. Because parts of 
AD pathology overlap with the pathology of other age-related neurodegenerative 
diseases, this push to discover and implement effective therapy may result in treatment 
options for a number of other disorders, including the tauopathy progressive 
supranuclear palsy (PSP). Likewise, research into the pathogenesis of PSP could have 
implications for treating AD and other tauopathies. 
Close examination of genetic risk factors for neurodegenerative disease is one 
way to identify important pathogenic disease pathways and discover new inroads to 
potential therapies. Large-scale genome-wide association screens (GWAS) and, more 
recently, whole exome sequencing studies have provided researchers with a wealth of 
information about potential contributors to neurodegenerative disease pathogenesis 
(Desikan et al., 2015; Höglinger et al., 2011; Jun et al., 2015; Lambert et al., 2013; Naj et 
al., 2011). Risk genes identified by SNP genotyping serve as “signposts” of risk—a 
genome-wide significant SNP may not be the risk-conferring variant in and of itself. 
Rather, the “hit” SNP is likely in high linkage disequilibrium (LD) with the true genetic 
source of increased disease risk. The previous chapters detail and explore in-depth one 
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example of this: the PSP risk gene EIF2AK3, which codes for the PERK protein. Though 
the GWAS signal from EIF2AK3 came from an intronic SNP (rs7571971), that SNP was 
in near complete LD with three SNPs that alter PERK protein coding (rs867529, 
rs13045, and rs1805165). These PERK coding variants are functionally different from 
one another (Liu et al., 2012) and are likely to be the source of increased PSP risk from 
EIF2AK3. 
PERK activation in neurodegenerative disease 
Chapter 2 of this dissertation provides biological evidence that PERK is 
associated with tau pathology in the brain. In a comparison of post-mortem brain tissue 
from PSP, AD and normal controls, the greatest number of phosphorylated PERK-
positive cells were in brain regions highly affected in each disease. pPERK and peiF2α 
were highest in the brainstem in PSP and in the hippocampus in AD. This puts PERK “at 
the scene of the crime” not only in PSP, but also in AD and in some elderly controls 
(Stutzbach et al., 2013). This also confirms and expands upon similar findings from other 
groups (J J M Hoozemans et al., 2007; Jeroen J M Hoozemans et al., 2009; D. a T. 
Nijholt et al., 2011). pPERK postitive cells also tended to be positive for htau, especially 
diffuse htau. This suggests that PERK activation precedes formation of neurofibrillary 
tangles (NFTs) and thus may be an early event in disease pathogenesis. This, too, 
reinforces findings from other groups (Jeroen J M Hoozemans et al., 2009).  
Intriguingly, some elderly controls exhibited moderate pPERK staining in the 
hippocampus. A correlation analysis demonstrated that PERK activation increased with 
both age and tau pathology. This novel finding suggests that PERK activation and tau 
both tend to increase in the aging brain. Whether PERK and tau directly influence one 
another is a question for future study. PERK may affect tau pathology in one or more 
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steps of the pathogenic process: 1.) PERK could influence whether a cell forms 
aggregates, either at the point of protein delivery to the cytoplasm or at the point of 
aggregation and/or 2.) PERK could influence downstream effects of tau aggregation. 
The UPR and tau intersect in several protein degradation pathways, including the 
proteasome system (Yen, 2011), which is the target of the ERAD pathway (Travers et 
al., 2000), and the endosome to lysosome pathway (Guo & Lee, 2011).  
Another finding that could account for the connection between PERK variation 
and tauopathy is the association of tau with the rough endoplasmic reticulum (Iqbal et 
al., 2009). Recent work demonstrated that abnormally phosphorylated tau partially 
colocalized with several subcellular compartments, including the ER (Tang et al., 2015). 
This colocalization would bring tau aggregates and the UPR machinery in close 
proximity, providing an opportunity for these two processes to interact more directly with 
one another. 
One cell culture model that could be useful to investigating this question was 
established by the Lee group at University of Pennsylvania (Guo & Lee, 2011). Guo and 
Lee (2011) transduced pre-formed tau fibrils (pffs) into QBI-293 cells expressing 
exogenous tau. This transduction resulted in formation of NFT-like tau aggregates within 
a matter of hours. Strikingly, incubating these same tau-expressing cells in media 
containing tau pffs resulted in spontaneous endocytosis-mediated uptake of these 
protein seeds and subsequent tangle formation, even in the absence of a protein 
delivery reagent. This model is thus useful for studying intracellular tau aggregation, 
abnormal tau degradation, and/or tangle-induced toxicity in cell culture and also could 
provide insight into cellular processes that affect uptake of abnormal tau and delivery to 
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the cytoplasm. Other potentially useful cell culture models of tau aggregation use 
fluorescently tagged tau to monitor aggregation in real time (reviewed in Lim et al. 2014) 
and may bypass some of the experimental drawbacks of post-fixation examination of tau 
aggregation.  
Using one of these cell culture models of tau aggregation, future work could 
examine 1) whether/when PERK is activated during the uptake, seeding, or aggregation 
process and 2) whether perturbing PERK affects tau uptake, seeding, or aggregation. 
PERK could be manipulated in several ways: 1) Gross pharmacological induction of the 
UPR via thapsigargin (Rogers et al., 1995) or tunicamycin (Elbein, 1987) 2) specific 
pharmacological prolongation of eIF2α phosphorylation via salubrinal (Boyce et al., 
2005) 3) expression and activation of a stress-independent, drug-inducible PERK 
construct (Fv2E-PERK; Lu et al., 2004) 4) PERK knockdown via RNAi 5) PERK 
inhibition via treatment with GSK2656157 (Atkins et al., 2013) or 6) expression of the 
PERK variant constructs detailed in Chapter 3 of this dissertation. 
PERK variation and its effect on PERK function 
Chapter 2 also presents data supporting the hypothesis that a three amino acid 
coding variant haplotype of the PERK protein, HapB, contributes to PSP risk (Stutzbach 
et al., 2013). HapB PERK induces higher levels of eIF2α phosphorylation in response to 
thapsigargin treatment than does HapA PERK (Liu et al., 2012). Because the higher 
activity HapB PERK is also higher risk for PSP, it follows that this increased activity is 
not adaptive and may actually be pathogenic. One explanation for this could be that 
prolonged phosphorylation of eIF2α damages the neuron via extended translational 
inhibition (Moreno et al., 2012). Continual synthesis of new proteins and 
neurotransmitters are essential to neuronal function in general and memory formation in 
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particular. Long-term potentiation (LTP), an important component of memory formation 
at the cellular level, is inhibited by eIF2α phosphorylation (Ma et al., 2013), and an over-
active eIF2α kinase could disrupt this important process.  
Thus, though PERK activation in the short-term and in moderation may be 
adaptive, extended PERK activity may irreparably damage a neuron. Even a modest 
increase in PERK activity might bias a cell toward dysfunction, especially as pathological 
protein aggregates accumulate in the cytoplasm and challenge homeostasis in myriad 
ways. It could be that as we age, our neurons are more vulnerable to these stressors as 
more pathological proteins accumulate, increasing the likelihood of cell death in 
response to a challenge. 
Chapter 3 explores the origin of this differential eIF2α kinase activity between 
HapA and HapB. HapB is composed of the following three amino acid variations: 
Ser136Cys, Arg166Gln, and Ser704Ala. Amino acids 136 and 166 are located on the 
luminal, dimerization end of the PERK protein; amino acid 704 is on the cytoplasmic, 
kinase-domain side of the protein. Though all three coding variants are usually inherited 
together (Liu et al., 2012; Stutzbach et al., 2013), it is possible that only one of the 
changes is responsible for the difference in activity between the two versions of the 
PERK protein.  
This work explores this possibility in two ways. First, data from Chapter 3 
replicated the finding from Liu et al. (2012) that HapB PERK phosphorylates more eIF2α 
in response to thapsigargin treatment than does HapA. Seemingly in contrast, HapB β-
lymphocytes also showed relatively less PERK phosphorylation in response to this same 
drug treatment. If this effect is not due to a difference in pPERK antibody affinity 
   
83 
 
between the haplotypes, it could indicate that HapB is actually less likely to 
transautophosphorylate and more likely to phosphorylate eIF2α. Future work should 
explore this possibility. 
Expressing artificial PERK variants with these individual amino acid changes in 
PERK null mouse embryonic fibroblasts (MEFs) did not yield significant differences in 
PERK activity. However, these results suggest a trend toward HapB-expressing cells 
having a stronger response to tg treatment. HapB expressing cells showed a bigger 
difference between baseline levels of pPERK, peIF2α, and ATF4 and these same levels 
after tg treatment. This difference in the magnitude of response to thapsigargin between 
HapA and HapB echoes the findings in β-lymphocytes discussed above. Interestingly, 
MEFs expressing the single amino-acid variant PERK constructs may have an 
“intermediate” effect on thapsigargin response, though the current data are only 
preliminary given the lack of statistical significance. 
Further study into functional variations of PERK should also examine how post-
translational modifications affect differences in activity between HapA and HapB. HapA 
contains two serines (S136 and S704) not present in HapB. Phosphorylation at either of 
these sites could potentially affect activity. Thus, future studies could incorporate PERK 
constructs pseudophosphorylated at these sites (136E and 704E). Conversely, this work 
could also examine activity of PERK that is unphosphorylatable and incapable of 
disulfide bonding at residue 136 (136A). Another way to approach this question would be 
to determine by mass spectrometry whether either of these serines are phosphorylated 
on endogenously expressed HapA PERK, either at baseline or in response to stress. 
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It may be that PERK -/- MEFs are not an ideal model to study PERK variation 
and its contribution to disease pathogenesis. Because PERK plays a role in 
neurodegeneration, future work could benefit from using neuronal cultures to explore this 
question. The specialized functions of neurons and their heavy reliance on protein 
translation may make them especially vulnerable to sustained PERK activation. Though 
there are, as of yet, no neuronal cell culture models of tau aggregation (Guo & Lee, 
2014), this type of system would be ideal for studying the interaction between PERK 
variation and tau pathogenesis. 
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